

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA

ORACLE CORPORATION, ET AL., Case No. 11-00910 JCS

Plaintiffs,

**CLAIM CONSTRUCTION ORDER**

v.

DRUGLOGIC, INC.,

Defendant

DRUGLOGIC, INC.,

Counterclaimant,

v.

ORACLE CORPORATION, ET AL.,

Counterclaim-Defendants.

**I. INTRODUCTION**

Plaintiffs Oracle Corporation and Oracle International Corporation (“Oracle”) filed this action against Defendant DrugLogic, Inc. (“DrugLogic”) alleging infringement by DrugLogic of Oracle’s U.S. Patent No. 6,684,221 (“the ‘221 patent”) and seeking a declaratory judgment of non-infringement and invalidity as to DrugLogic’s U.S. Patent No. 6,789,091 (“the ‘091 patent”). DrugLogic, in turn, brings a counterclaim alleging that Oracle is infringing the ‘091 patent. The parties submitted ten claim terms for construction, consistent with Patent Local Rule 4-3 and the Court’s Case Management and Pretrial Order [Docket No. 55]. A tutorial was conducted on July 11,

1 2012 and a claim construction hearing was held the following day, on July 12, 2012. The Court's  
2 final constructions are set forth below.<sup>1</sup>

3 **II. THE PATENTS-IN-SUIT**

4 The patents-in-suit relate to the field of pharmacovigilance, which is the collection and  
5 analysis of data regarding the risks of adverse effects from the use of a particular drug.

6 **A. The '091 patent**

7 The '091 patent is entitled "Method and System for Web-Based Analysis of Drug Adverse  
8 Effects." The named inventor is Victor Gogolak. The application for the '091 patent was filed on  
9 May 2, 2001. As originally drafted, claims 1 and 8 of the '091 patent read as follows:

10 1. A computer-implemented method for assessing and analyzing the risks of adverse effects  
11 resulting from the use of at least one [drug/substance]<sup>2</sup> of interest, comprising:  
12     storing data regarding the risks of adverse effects from the use of at least one  
[drug/substance] of interest in one or more servers linked to the Internet;  
13     updating such data regarding the risks with additional information pertinent to the risks of  
adverse effects from the use of the at least one [drug/substance] of interest;  
14     permitting at least one remote user to access such data through the World Wide Web upon  
proper authentication;  
15     permitting the at least one user to identify the at least one [drug/substance] of interest;  
16     permitting the at least one remote user to select data stored in the one or more servers  
relevant to the safety of using the at least one [drug/substance] of interest;  
17     permitting the at least one remote user to analyze safety issues resulting from the use of the  
at least one [drug/substance] of interest; and  
18     permitting the at least one remote user to display such data and analysis.

19 Declaration of Christina Von Der Ahe in Support of Oracle's Brief Regarding the Construction of  
20 the Disputed Terms in the '091 Patent ("Von Der Ahe Decl."), Ex. I ('091 Application). In an  
21 Office Action dated June 18, 2003, the Patent and Trademark Office ("PTO") rejected all of the  
22 original claims in the application over prior art. Von Der Ahe Decl., Ex. J (Office Action). In  
23  
24

---

25  
26     <sup>1</sup>The parties have consented to the jurisdiction of the undersigned United States Magistrate Judge  
27 pursuant to 28 U.S.C. § 636(c).

28     <sup>2</sup>Claim 1 uses "drug" throughout whereas claim 8 uses "substance" throughout.

1 response, the inventor added to the end of original claims 1 and 8 the following clause (hereinafter,  
2 “the Wherein Clause”):

3 wherein the step of permitting the at least one remote user to analyze comprises associating  
4 respective hyperlinks with a plurality of portions of such data and analysis, the plurality of  
5 hyperlinks respectively corresponding to places in an up and down hierarchy and allowing  
6 analytical drill down by selectively selecting successive hyperlinks, a last one of the  
7 hyperlinks in the up and down hierarchy linking to a previously-stored case describing  
8 adverse effects resulting from the use of the at least one drug of interest.

9 Von Der Ahe Decl., Ex. K at 3-4, 6 (March 4, 2004 Amendment). With that amendment, the claims  
10 were allowed and the ‘091 patent issued on September 7, 2004.

#### 9           **B.       The ‘221 patent**

10 The ‘221 patent is entitled “Uniform Hierarchical Information Classification and Mapping  
11 System.” The inventor, Kim Rejndrup, who was an Oracle employee, applied for the patent on May  
12 8, 2000. The original application included 63 claims, including original claim 1, which stated as  
13 follows:

14 A method of storing clinical terms comprising defining a plurality of clinical terms; storing  
15 the clinical terms in a memory; and defining a plurality of relations corresponding to the  
16 plurality of clinical terms, the relations indicative of an association from a clinical term to at  
17 least one other of the plurality of clinical terms.

18 Declaration of Christina Von Der Ahe in Support of Oracle’s Reply Brief Regarding the  
19 Construction of Disputed Terms in the ‘221 patent (“Von Der Ahe Reply Decl.”), Ex. A (‘221 patent  
20 Prosecution History) at 16.

21 On August 21, 2002, the PTO rejected claim 1 as obvious “over Coulter et al. (U.S. Patent  
22 No. 5,201,048), Nakajima et al. (U.S. Patent No. 5,181,163), and Sasmor et al. (U.S. Pat. No.  
23 4,825,968).” *Id.*, Ex. B (Office Action dated August 21, 2002) at 2-3. The PTO found that: (1) the  
24 Coulter reference taught defining terms and storing terms in a memory; (2) the Nakajima reference  
25 taught defining relations and the association of relations; (3) the Sasmor reference taught the use of  
26 clinical terms; and (4) it would have been obvious to one of ordinary skill in the art to combine these  
27 references. *Id.*

1 Oracle's response to the rejection was received by the PTO on December 2, 2002. *Id.*, Ex. F  
2 (Amendment A to application, dated December 2, 2002). Oracle argued that it would not have been  
3 obvious to combine Coulter, Nakajima, and Sasmor because they occupy different fields and  
4 amended its claims to reflect the aspect of the invention it argued was non-obvious, the storing of  
5 clinical terms in a memory "according to a hierarchy of relations." *Id.* at 6-7. For example, Oracle  
6 amended claim 1 to add the underlined phrase:

7 A method of storing clinical terms comprising defining a plurality of clinical terms; storing  
8 the clinical terms in a memory according to a hierarchy of relations; and defining a plurality  
9 of relations corresponding to the plurality of clinical terms, the relations indicative of an  
association from a clinical term to at least one other of the plurality of clinical terms.

10 *Id.* at i (underlined in Oracle's response to PTO rejection).

11 On February 7, 2003, the PTO again rejected all the claims of the patent. *Id.*, Ex. G (Office  
12 Action dated February 7, 2003). The Examiner found that claim 1 was obvious over Coulter,  
13 Nakajima, Sasmor and Gusak (U.S. Patent No. 6,112,209). *Id.* In particular, the Examiner found  
14 that although neither Coulter, Nakajima nor Sasmor taught storing clinical terms "according to a  
15 hierarchy of relations," such storage was taught by Gusak. *Id.* at 2-3.

16 On June 13, 2003, the applicant again amended the claims, amending claim 1 as follows:

17 A method of storing a thesaurus of clinical terms comprising defining a plurality of clinical  
18 terms for use in conjunction with a clinical study; storing the plurality clinical terms in a  
19 memory according to a hierarchy of relations; and defining a plurality of relations  
corresponding to the clinical terms, the relations indicative of an association from a clinical  
term to at least one other of the plurality of clinical terms.

20 *Id.*, Ex. I at i (underlined in Oracle's response to PTO rejection). Oracle explained that the  
21 amendments were intended to "specify, with more particularity, that the invention relates to a  
22 thesaurus of clinical terms for use in conjunction with a clinical study." *Id.* at 6. Oracle argued that  
23 "none of the cited [prior art] references relate to clinical studies" and none of those references  
24 "address the issues associated with clinical studies, such as the inconsistencies in terminology in the  
25 medical field." *Id.* at 8. On October 17, 2003, the PTO allowed the claims as amended. *Id.*, Ex. J  
26 (Notice of Allowability).

27 The Abstract of the '221 patent describes the invention as follows:

28

1 A system and method to access and update a thesaurus of clinical terms employed in  
2 conjunction with a clinical study can be used to classify and map the clinical terms to related  
3 terms. A study term extracted from raw clinical data is presented to determine a  
4 corresponding match in the thesaurus of clinical terms. A table of relations is maintained to  
5 associate each clinical term with one or more related clinical terms in the thesaurus. A  
6 clinical term is mapped to one or more derived terms as indicated by the relations. The  
7 derived terms are processed to select a preferred term from the derived terms. An omission  
8 manager is operable to find a near matching candidate term if the clinical term is not found in  
9 the thesaurus. A plurality of different clinical terms can therefore be classified as  
10 corresponding to a common clinical term as indicated by the relations.

11 '221 patent, Abstract.

12 Two of the three disputed claim terms are found in claim 1, which states as follows:

13 1. A method of storing a thesaurus of **clinical terms**  
14 comprising:

15 **defining a plurality of clinical terms for use in conjunction  
16 with a clinical study;**

17 storing the plurality of clinical terms in a memory according  
18 to a hierarchy of relations; and

19 defining a plurality of relations corresponding to the clinical  
20 terms, the relations indicative of an association from  
21 a clinical term to at least one other of the plurality of  
22 clinical terms.

23 '221 patent, claim 1 (disputed claim terms in bold). The third disputed claim term is found in claim  
24 12, a dependent claim which depends from dependent claim 2. Claim 2 recites the following:

25 2. The method of claim 1, further comprising:

26 storing the relations in the memory;

27 providing a match term;

28 querying the memory to find an occurrence of the match  
29 term;

traversing the relations corresponding to the match term;  
30 and

31 accumulating at least one derived term from the relations corresponding to the match term.

32 '221 patent, claim 2. Claim 12 states as follows:

33 12. The method of claim 2 wherein providing a match  
34 term further comprises:

35 scanning **verbatim clinical data**; and

1                   parsing verbatim study terms from the clinical data,  
2                   wherein the verbatim study terms include the match  
3                   terms.

4                   ‘221 patent, claim 12.

5                   The claims of the ‘221 patent were allowed, as amended, on November 17, 2003. Von Der  
6                   Ahe Reply Decl., Ex. J.

### 7                   **III. CLAIM CONSTRUCTION STANDARDS**

8                   “It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the invention to  
9                   which the patentee is entitled the right to exclude.’” *Phillips v. AWH Corp.*, 415 F.3d 1303, 1312  
10                  (Fed. Cir. 2005) (quoting *Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc.*, 381 F.3d  
11                  1111, 1115 (Fed. Cir. 2004)). Generally, claim terms are given the ordinary and customary meaning  
12                  that would be ascribed to them by a person of ordinary skill in the field of the invention. *Id.* at 1313;  
13                  see also *Rexnord Corp. v. Laitram Corp.*, 274 F.3d 1336, 1342 (Fed. Cir. 2001) (“[U]nless compelled  
14                  to do otherwise, a court will give a claim term the full range of its ordinary meaning as understood  
15                  by an artisan of ordinary skill”).

16                  The most “significant source of the legally operative meaning of disputed claim language” is  
17                  the intrinsic evidence of record, that is, the claims, the specification and the prosecution history.  
18                  *Vitronics Corp. v. Conceptronic, Inc.*, 90 F.3d 1576, 1582 (Fed. Cir. 1996). This is because “the  
19                  person of ordinary skill in the art is deemed to read the claim term not only in the context of the  
20                  particular claim in which the disputed term appears, but in the context of the entire patent, including  
21                  the specification.” *Phillips*, 415 F.3d at 1312. In some cases, the specification may reveal a “special  
22                  definition” given by the inventor that differs from the meaning the term might otherwise possess. *Id.*  
23                  at 1316. In such instances, “the inventor’s lexicography governs.” *Id.* Similarly, a specification  
24                  may reveal “an intentional disclaimer, or disavowal, of claim scope by the inventor.” *Id.*

25                  A person of ordinary skill in the art also looks to the prosecution history of a patent to  
26                  understand how the patent applicant and the PTO understood the claim terms. *Id.* at 1313, 1317.  
27                  Under the doctrine of prosecution disclaimer, arguments and amendments made during patent  
28                  prosecution limit the interpretation of claim terms to exclude interpretations that were disclaimed to

1 obtain allowance of a claim. *Southwall Technologies, Inc. v. Cardinal IG Co.*, 54 F.3d 1570, 1576  
2 (Fed. Cir. 1995). However, there is a heavy presumption that terms carry their full ordinary and  
3 customary meaning unless the patentee “unequivocally imparted a novel meaning to those terms or  
4 expressly relinquished claim scope during prosecution.” *Omega Engineering, Inc. v. Raytek Corp.*,  
5 334 F.3d 1314, 1323 (Fed. Cir. 2003) (citation omitted). Therefore, the Federal Circuit has declined  
6 to apply the doctrine of prosecution disclaimer “where the alleged disavowal of claim scope is  
7 ambiguous.” *Id.* at 1324.

8 While claims are to be construed in light of the specification, courts must be careful not to  
9 read limitations from the specification into the claim. *Phillips*, 415 F.3d at 1323. Thus, for example,  
10 if a patent specification describes only a single embodiment of a claimed invention, that does not  
11 mean the claims of the patent necessarily must be construed as limited to that embodiment. *Id.*  
12 Rather, it is understood that the purpose of the specification “is to teach and enable those of skill in  
13 the art to make and use the invention” and that sometimes, the best way to do that is to provide an  
14 example. *Id.*

15 Courts may also use extrinsic evidence in construing claim terms if it is necessary, so long as  
16 such evidence is not used to “vary or contradict the terms of the claims.” *Markman v. Westview*  
17 *Instruments, Inc.*, 52 F.3d 967, 980 (Fed. Cir. 1995). As the court explained in *Markman*,  
18 “[extrinsic] evidence may be helpful to explain scientific principles, the meaning of technical terms,  
19 and terms of art that appear in the patent and prosecution history.” *Id.* The Federal Circuit has  
20 warned, however, that such evidence is generally “less reliable than the patent and its prosecution  
21 history.” *Phillips*, 415 F.3d at 1318. Thus, courts are free to consult dictionaries and technical  
22 treatises so long as they are careful not to elevate them “to such prominence that it focuses the  
23 inquiry on the abstract meaning of the words rather than on the meaning of the claim terms within  
24 the context of the patent.” *Id.* at 1321-22.

25  
26  
27  
28

1 **IV. CONSTRUCTION OF CLAIM TERMS**2 **A. The '091 Claim Terms**3 **1. Claim Terms in the Wherein Clause of Claims 1 and 8**4 **a. "allowing analytical drill down"**5 **i. The Parties' Positions**

6 Druglogic's Proposed Construction	7 Oracle's Proposed Construction
7 "allowing the user to further analyze data by 8 accessing more detailed, narrow, or granular information"	8 "allowing a user to redo the analysis in real time at different levels of the hierarchy"

9 Druglogic contends that the term "allowing analytical drill down" means "allowing the user  
10 to further analyze data by accessing more detailed, narrow, or granular information." Druglogic  
11 Inc.'s Opening Claim Construction Brief on United States Patent No. 6,789,091 ("Druglogic's  
12 Opening Brief ('091 patent") at 18. In support of its proposed construction, Druglogic cites two  
13 passages in the specification that use the words "drill down," col. 9, ll. 10-28 and col. 9, l. 66 - col.  
14 10, l. 5. *Id.* The first passage states as follows:

15 Preferably, if the user is reviewing a previously submitted correlation task at the  
16 Correlated Terms Line Listing Box 105, the present invention permits the user to access the  
17 case list at the Case List Box 106, and further, permits the user to drill down on the  
individual elements in the case list and obtain case details in the Case Details Box 107.

18 Preferably, if the user is querying the system with regard to a drug at Drug Selector  
19 Page Box 111, then the present invention permits the user to access the drug profile at the  
20 Profile Page Box 112, further, permits the user to access the case list at the Case List Box  
21 113, and still further, permits the user to drill down on individual elements in the case list  
and obtain case details at the Case Details Box 114.

22 '091 patent, col. 9, ll. 10-28. The second passage states:

23 The output from the data mining engines is then preferably displayed in a Viewer 205, which  
24 can present the data in a variety of formats, including, but not limited to a sortable table, a  
sortable line listing, and a radar screen, thus allowing rapid identification of signals and  
providing the user the ability to drill down to individual case details.

25 '091 patent, col. 9, l. 66 - col. 10, l. 5.

1 Druglogic also cites to extrinsic evidence in support of its proposed construction. *Id.* at 19.  
2 First, it cites to a definition of “drill down” from a Free On-Line Dictionary of Computing, or  
3 “FOLDOC,” which defines that term as follows:

4 **drill down**

5 *<database>* (Or “drill-down analysis”) To examine data in greater detail, especially, in  
6 reporting, to interactively select some item from a summary and display the data that  
contributed to that item, broken down by some extra parameter.

7 For example, when viewing your company’s total worldwide sales for each month of this  
8 year, you might drill down to see October’s sales by country, then again to see October’s  
sales in Afghanistan by product and so on.

9 This kind of analysis is often supported by some kind of data warehouse.

10 *Id.*, Ex. 8.<sup>3</sup>

11 Second, Druglogic cites to a 2012 Wikipedia definition of “drill down,” which states as  
12 follows:

13 In information technology, to drill down means to move from summary information to  
14 detailed data by focusing in on something. In a [graphical user interface]-environment,  
‘drilling-down’ may involve clicking on some representation in order to reveal more detail.

15 To drill down through a series of folders, for example, on a desktop means to move through  
16 the hierarchy of folders (from the top downwards) to find a specific file or to click through  
17 drop-down menus in a [graphical user interface]. Clicking on an item moves you to a level of  
greater detail....

18 Drilling down through a database involves accessing information by starting with a general  
19 category and moving through the hierarchy: from category to file/table to record to field.  
When one drills down, one performs de facto data analysis on a parent attribute. Drilling  
20 down provides a method of exploring multidimensional data by moving from one level of  
detail to the next. Drill-down levels depend on the data granularity.

21 *Id.*, Ex. 10 (excerpt from Wikipedia, [http://en.wikipedia.org/wiki/Drill\\_down](http://en.wikipedia.org/wiki/Drill_down), (2012)).

22 Third, Druglogic cites to the glossary in an Oracle user’s manual which defines “drilldown”  
23 as “[t]he process of uncovering more detailed information about the cases that are included in data  
24 mining run results, in a case series, or in a report.” *Id.*, Ex. 4.

25  
26 \_\_\_\_\_  
27 <sup>3</sup>DrugLogic attached its extrinsic evidence as exhibits to its brief without providing a declaration  
28 authenticating the documents. DrugLogic did not provide a web address or publication date for the  
FOLDOC definition.

1       Finally, Druglogic argues that its proposed construction makes sense in light of “the entire  
2 language” of claims 1 and 8. *Id.* In particular, the words “places in an up and down hierarchy”  
3 refers to subsets of information “which are more or less specific relative to one another.” *Id.* Thus,  
4 DrugLogic asserts, “analytical drill down” is “simply the act of clicking through the hyperlinks  
5 within the hierarchy to obtain more detailed information.” *Id.* Similarly, the words following the  
6 phrase “allowing analytical drill down,” that is, “by selectively selecting successive hyperlinks, a  
7 last one of the hyperlinks in the up and down hierarchy linking to a previously stored case . . .” refer  
8 to the process of drilling down on successive hyperlinks within the hierarchy, lending further  
9 support to DrugLogic’s proposed construction, it contends. *Id.* at 20.

10       Oracle rejects DrugLogic’s proposed construction, which it characterizes as “generic,” on the  
11 grounds that: 1) at the time of the invention, the term “allowing analytical drill down” did not have  
12 an ordinary meaning; and 2) the patentee provided its own definition of the term in the specification.  
13 Oracle’s Brief Regarding the Construction of Disputed Terms in the ‘091 patent (“Oracle  
14 Responsive Brief (‘091 patent)”) at 7. In support of the first point, Oracle cites to the declaration of  
15 Stephen Jolley, an expert in drug safety auditing and compliance, who states that “[i]n May 2001,  
16 when the ‘091 Patent was filed, the term ‘analytical drill down’ did not have a commonly-  
17 understood meaning to one of ordinary skill in the fields of drug safety and pharmacovigilance.” *Id.*  
18 (citing Declaration of Stephen Jolley in Support of Oracle’s Brief Regarding the Construction of  
19 Disputed terms in the ‘091 Patent (“Jolley Decl.”), ¶ 18).

20       Mr. Jolley further states that “[a]s one of ordinary skill in the art in May 2011 . . . [he] would  
21 have understood ‘analytical drill down’ to mean that which it is defined to mean in Column 23, lines  
22 41-51 of the ‘091 patent.” Jolley Decl., ¶ 19. That section of the specification recites as follows:

23       The invention also allows “analytical drill down.” That is, the ability to redo the analysis, in  
24 a preferred case, for a drug and a reaction system-organ-class. The user then selects the level  
25 (e.g., PT) for re-analysis and is given the results in real time. The user can then iterate  
26 between high level and detail. It will be appreciated that the invention is not restricted to  
27 drug and reaction dimensions for proportional analysis. All pairs of the dimensions of the  
28 analytical engine (for example, reaction and outcomes) can be analyzed. Even within the  
cases of a single drug, the reactions and concomitant drugs could be proportionally analyzed.

‘091 patent, col. 23, ll. 41-51. According to Oracle, in this passage the patentee acted as his own

1 lexicographer, setting off the term “analytical drill down” in quotation marks and using the words  
2 “that is” to signal that a special definition is being provided. Oracle Responsive Brief (‘091 Patent)  
3 at 8 (citing *Sinorgchem Co., Shandong v. Int’l Trade Comm’n*, 511 F.3d 1132, 1136 (Fed. Cir.  
4 2007)). Accordingly, Oracle contends that the term “allowing analytical drill down” means  
5 “allowing a user to redo the analysis in real time at different levels of the hierarchy.” Oracle  
6 contends that its proposed construction tracks the definition of “analytical drill down” in the passage  
7 of the specification quoted above by making clear that the term means allowing a user to: “1) ‘redo  
8 the analysis’ 2) at a selected ‘level’ and 3) receive the results ‘in real time.’” *Id.*

9 The word “hierarchy” is not used in the definition provided in the specification but it is  
10 referred to, Oracle asserts. *Id.* In particular, according to Oracle’s expert, the references to “system-  
11 organ-class” and “PT” in that definition “refer to different levels of the MedDRA hierarchy.” Jolley  
12 Decl., ¶ 20. Mr. Jolley explains:

13 MedDRA, the Medical Dictionary for Regulatory Activities, is a standardized medical  
14 dictionary that stores and classifies terms according to a five-level hierarchy. The five levels  
15 of the hierarchy are System, Organ, Class (SOC); High Level Group Terms (HLGT); High  
Level Terms (HLT); Preferred Terms (PT), and Lower Level Terms (LLT).

16 *Id.* In other words, Oracle asserts, “[w]hen the ‘091 patent defines ‘analytical drill down’ as  
17 allowing a user to do an analysis on the ‘system-organ-class’ level and then on the ‘PT’ (Preferred  
18 Terms) level, to ‘select[] the level’ and to ‘iterate between high level and detail’, . . . the patent is  
19 describing the ability to perform the analytical drill down of the ‘091 patent at different levels of the  
20 *the MedDRA hierarchy.*” Oracle Responsive Brief (‘091 patent) at 9 (emphasis in original).

21 Oracle contends that DrugLogic’s proposed construction is incorrect because DrugLogic  
22 ignores the definition of the term that is provided in the specification (quoted above) “and attempts  
23 to construe the term ‘analytical drill down’ as no different from the phrase ‘drill down.’” *Id.* at 9-10.  
24 According to Oracle, the term “analytical drill down” is different from “drill down.” *Id.* at 10. This  
25 is apparent, Oracle asserts, from the fact that the passages in the specification cited by DrugLogic,  
26 which address “drill-down,” *see* ‘091 patent, col. 9, ll. 10-28 and col. 9, l. 66 - col. 10, l. 5, are  
27 followed – more than 10 columns later – by the statement that “[t]he invention *also allows*

28

1 ‘analytical drill down.’” *Id.* at 10 (quoting ‘091 patent, col. 23, l. 41). Oracle argues that this shows  
2 that the ‘091 patent “defines ‘analytical drill down’ as a different – and more specific – concept from  
3 ‘drill down.’” *Id.*

4 Oracle rejects DrugLogic’s reliance on a Wikipedia definition of “drill down,” arguing that  
5 that definition is irrelevant because it defines “drill down” rather than “analytical drill down” and is  
6 from 2012 rather than the time of the invention. *Id.* It also cites cases in which courts have noted  
7 that Wikipedia is “a particularly unreliable extrinsic source for purposes of claim construction.” *Id*  
8 (citing *Neev v. Abbott Med. Optics, Inc.*, 2012 U.S. Dist. LEXIS 42024, at \*34 (D. Del. March 26,  
9 2012); *F5 Networks Inc. v. A10 Networks, Inc.*, 2011 U.S. Dist. LEXIS 89515, at \*8 (W.D. Wash.  
10 Aug. 11, 2011)).

11 Finally, Oracle disagrees with DrugLogic’s contention that its proposed construction “makes  
12 sense in context with the entire language” of claims 1 and 8. *Id.* (quoting DrugLogic’s Opening  
13 Brief (‘091 patent) at 19). According to Oracle, this argument amounts to construing the term  
14 “analytical drill down” to fit better with DrugLogic’s “other arguments about what [c]laims 1 and 8  
15 mean.” *Id.* Instead, Oracle contends, the Court should take as its starting point the term that is  
16 actually defined in the specification (“analytical drill down”) and then construe the other disputed  
17 terms in claims 1 and 8 in a manner that is consistent with that definition. *Id.* at 11.

18 In its reply brief, DrugLogic does not respond to Oracle’s arguments relating to the extrinsic  
19 evidence cited in its opening brief, implicitly conceding that this evidence does not provide strong  
20 support for its proposed construction. Instead, DrugLogic focuses on the specification and claims of  
21 the ‘091 patent, arguing that Oracle’s position is flawed because: “1) it ignores the surrounding,  
22 unambiguous language of the claims, 2) it imports limitations from a preferred embodiment, 3) it  
23 misinterprets the specification’s discussion of the term, and 4) it disregards language in the  
24 specification that consistently describes ‘drill down’ as permitting the user to move from the  
25 statistical analysis to a case list to case details.” DrugLogic, Inc.’s Reply Brief on Claim  
26 Construction of United States Patent No. 6,789,091 (“DrugLogic’s Reply Brief (‘091 patent)”) at 10.  
27  
28

1       As to the first point, DrugLogic contends that the language of the “Wherein Clause” makes  
2 clear that the invention “merely *allows* analytical drill down and does not itself perform analysis  
3 during drill down,” *id.* at 11 (emphasis in original), and therefore, that the language in the  
4 specification on which Oracle relies, that is, col. 23, ll. 41-51, “read in proper context” means that  
5 “the invention *permits the user to analyze by giving the user ‘the ability to redo the analysis’* [i.e.,  
6 conduct the user’s own analysis].” *Id.* (emphasis in original). According to DrugLogic, Oracle’s  
7 proposed construction “attempts to read out the unambiguous claim language that the invention  
8 permits *the user* to analyze by allowing analytical drill down.” *Id.* (emphasis in original).

9       DrugLogic argues that its proposed construction is also consistent with the references to  
10 “drill down” throughout the specification and that Oracle’s attempt to distinguish “drill down” from  
11 “analytical drill down” has no basis. *Id.* DrugLogic points out that even if the term “analytical drill  
12 down” may have had no established meaning in 2001, Oracle’s expert conceded at his deposition  
13 that the terms “drill down” and “analytical” had established meanings. *Id.* (citing Ex. A (Jolley Dep.  
14 Excerpt) at 31-33). In particular, Mr. Jolley testified that “drill down would have been understood to  
15 mean “going from higher level information to more detailed information.” *Id.* (citing Ex. A at 31).  
16 He agreed that “analytical,” standing on its own, would have been understood to mean “of or  
17 relating to analysis or analytics, especially separating something into component parts or constituent  
18 elements.” *Id.* (citing Ex. A at 32). According to DrugLogic, “[s]eparating the statistical analysis  
19 into its component parts (i.e., the case details underlying the analysis) is precisely what DrugLogic’s  
20 construction provides and the ‘091 patent describes.” *Id.* at 12.

21       DrugLogic rejects Oracle’s contention that the words “that is” at column 24, line 40 of the  
22 ‘091 patent indicate that the language that follows is a definition of “analytical drill-down.” *Id.* at  
23 13. According to DrugLogic, because the specification uses the words “that is” rather than “is,” this  
24 section of the specification merely describes a preferred embodiment. *Id.* This conclusion finds  
25 further support, according to DrugLogic, in the fact that the words “that is” are followed by the  
26 words “in a preferred case.” *Id.* “It is axiomatic,” DrugLogic asserts, “that preferred embodiments  
27 are not permitted to be read into claims, particularly where, as is the case here, the entirety of the  
28

1 patent suggests otherwise.” *Id.* (citing *Comark Communs., Inc. v. Harris Corp.*, 156 F.3d 1182,  
2 1187 (Fed. Cir. 1998)). DrugLogic further contends that the passage of the specification cited by  
3 Oracle simply describes “a capability of the drill down step (*i.e.*, what the user can do with the  
4 information once he or she drills down) and does not denote exclusion or restriction.” *Id.* In this  
5 regard, DrugLogic points to the testimony of Mr. Jolley, who testified that the words “in a preferred  
6 case” mean “ideally” and are not mandatory. *Id.* n. 23.

Finally, with respect to Oracle’s proposed inclusion of real time analysis at different levels of the hierarchy, these limitations are inappropriate, DrugLogic contends, because the sentence in the specification from which they are drawn states that the user can “then” select the level in the hierarchy for reanalysis. *Id.* at 14 (citing ‘091 patent, col. 23, ll. 43-45). According to DrugLogic, this indicates that this is merely a “subsequent step that can be performed as part of a preferred embodiment.” *Id.*

## ii. Analysis

14 The Federal Circuit has “repeatedly encouraged claim drafters who choose to act as their  
15 own lexicographers to clearly define terms used in the claims in the specification.” *Sinorgchem Co.,*  
16 *Shandong v. International Trade Com'n*, 511 F.3d 1132, 1136 (Fed. Cir. 2007). Thus, in *Phillips v.*  
17 *AWH Corp.*, the Federal Circuit confirmed that “the specification may reveal a special definition  
18 given to a claim term by the patentee that differs from the meaning it would otherwise possess” and  
19 that “[i]n such cases, the inventor’s lexicography governs.” *Id.* (quoting *Phillips v. AWH Corp.*, 415  
20 F.3d 1303, 1316 (Fed.Cir.2005) (en banc)). While the question of whether language in a  
21 specification constitutes a definition turns on a number of factors, the Court finds that the language  
22 found in col. 23, lines 41-51 of the ‘091 patent reflects a clear intent on the part of the patentee to  
23 provide a special definition of the term “analytical drill down” and that Oracle’s proposed  
24 construction accurately reflects that definition.

25 In reaching its conclusion, the Court relies on several factors. First, the Court finds that the  
26 language and punctuation of this passage are definitional. The fact that the words “analytical drill  
27 down” are set off by quotation marks is a “strong indication that what follows is a definition.” *See*

1 *Sinorgchem Co., Shandong v. International Trade Com'n*, 511 F.3d 1132, 1136 (Fed. Cir. 2007)  
2 (holding that language in specification defined a claim term based, in part, on the fact that term was  
3 set off by quotation marks and noting that this is "often a strong indication that what follows is a  
4 definition"). Similarly, the use of the words "that is" indicate that the inventor was giving the term  
5 "analytical drill down" a special meaning. *Trading Technologies Intern., Inc. v. eSpeed, Inc.*, 595  
6 F.3d 1340, 1353 (Fed. Cir. 2010) (holding that "the inventors acted as their own lexicographers and  
7 defined the term 'static'" based on the following disclosure in the specification: "The values in the  
8 price column are static; *that is*, they do not normally change positions unless a re-centering  
9 command is received").

10 The Court rejects DrugLogic's contention that the words "in a preferred case" indicate that  
11 the language in this passage merely references a "preferred embodiment." Rather, the Court  
12 concludes that the words "in a preferred case" modify the words "for a drug and a reaction system-  
13 organ-class." These words do not indicate that the definition provided in this section of the  
14 specification applies only to one particular embodiment. In the alternative, even if the term *is*  
15 defined in the context of describing a preferred embodiment, the language of the specification makes  
16 clear that the inventors were offering a special definition of "analytical drill down" for the '091  
17 invention and that definition governs. The Court also rejects DrugLogic's suggestion that the word  
18 "then" indicates that the language that follows, relating to analysis performed by the user at different  
19 levels of the hierarchy, refers to an "additional step." The only expert testimony in the record on this  
20 question is Mr. Jolley's, and he expressed a contrary view, namely, that the user's selection of the  
21 level for reanalysis is *part of* "analytical drill down" rather than a subsequent step. *See*  
22 DrugLogic's Reply Brief, Ex. A (Jolley Depo.) at 102. He further testified that this language  
23 indicated that the user was given the results of the re-analysis in real time. *Id.*

24 Second, while it is undisputed that the term "drill down" had an established meaning at the  
25 time of the invention, DrugLogic has offered no evidence that controverts the testimony of Oracle's  
26 expert that at the time of the invention the term "analytical drill down" had no established meaning.  
27 Nor has DrugLogic offered any expert testimony challenging the testimony of Oracle's expert that  
28

1 the language in the specification found in column 23 at lines 41-45 would have been understood by a  
2 person of ordinary skill in the art as a definition of “analytical drill down.”

3       Third, the Court finds unpersuasive DrugLogic suggestion that “analytical drill down” and  
4 “drill down” were used interchangeably in the ‘091 patent as DrugLogic has offered no explanation  
5 for the inventor’s use of two different terms to convey the same concept. Further, DrugLogic’s  
6 position is contradicted by the fact that the passage quoted above begins with the statement that the  
7 “invention *also* allows ‘analytical drill down.’” ‘091 patent, col. 23, l. 41 (emphasis added). Given  
8 that two examples of “drill down” are described in passages of the specification that precede this  
9 statement, *see* ‘091 patent col. 9, ll. 10-28 and col. 9, l. 66 - col. 10, l. 5, the most logical reading of  
10 this statement is that “analytical drill down” is something different from “drill down.”

11       The Court also rejects DrugLogic’s reliance on *Abbot Labs. v. Andrx Pharms., Inc.*, 473 F.3d  
12 1196, 1210 (Fed. Cir. 2007) to support its position that the language in the ‘091 specification is not  
13 definitional. In that case, the Federal Circuit held that the phrase “[t]he pharmaceutically acceptable  
14 polymer is a water-soluble hydrophilic polymer” was not an explicit definition of the term  
15 “pharmaceutically acceptable polymer” because: 1) the inventors had provided other special  
16 definitions in the same patent by explicitly stating that those terms had a special meaning rather than  
17 using the more ambiguous “is” construction; 2) neither party’s expert offered testimony that the  
18 phrase would have been construed as a definition by a person of ordinary skill in the art; and 3) the  
19 language of the claims themselves did not support such a construction. None of the reasons that  
20 supported the holding in *Abbot Laboratories* applies here. First, as noted above, the language in the  
21 ‘091 specification is not ambiguous but rather, signifies that a definition is being provided; nor has  
22 DrugLogic pointed to other definitions in the ‘091 specification in which clearer language was used  
23 to convey that the inventors were offering a special definition. Second, Oracle’s expert opined that  
24 the language would have been understood as definitional by a person of ordinary skill in the art.  
25 Finally, the language of the claims does not suggest that the disclosure in the specification should  
26 not be construed as a definition.

27       Finally, the Court finds that Oracle’s proposed construction accurately conveys the definition  
28

1 of “analytical drill down” set forth in col. 23, lines 41-45 of the ‘091 patent. Therefore, the Court  
2 construes “allowing analytical drill down” as follows: “allowing a user to redo the analysis in real  
3 time at different levels of the hierarchy.”

4 **b. “hyperlinks . . . corresponding to places in an up and down  
hierarchy”**

5 **i. The Parties’ Positions**

6 DrugLogic’s Proposed Construction	7 Oracle’s Proposed Construction
7 No construction required 8 or 9 “hyperlinks . . . corresponding to subsets of 10 information of more or less specificity relative to one another”	“such links . . . corresponding to different levels of a structured medical dictionary, such as MedDRA”

12 DrugLogic contends that the term “hyperlinks . . . corresponding to places in an up and down  
13 hierarchy” is readily understandable to a lay jury and therefore requires no construction.

14 DrugLogic’s Opening Brief (‘091 patent) at 15 (citing *EON Corp. IP Holdings, LLC v. Sensus USA*  
15 *Inc.*, 741 F. Supp. 2d 783, 813 (E.D. Tex. 2010)). If the Court finds that construction is necessary,  
16 however, DrugLogic proposes that the term be construed as “hyperlinks . . . corresponding to subsets  
17 of information of more or less specificity relative to one another.” *Id.* In support of its position,  
18 DrugLogic quotes an on-line dictionary that includes as one meaning of “hierarchy” “[a]ny system  
19 of . . . things ranked one above another.” *Id.*, Ex. 7. DrugLogic also points to the FOLDOC  
20 definition of “hierarchy” as “[a]n organisation with few things, or one thing, at the top and with  
21 several things below each other thing.” *Id.*, Ex. 8.

22 According to DrugLogic, Oracle’s proposed construction – “such links . . . corresponding to  
23 different levels of a structured medical dictionary, such as MedDRA” – improperly imports  
24 limitations from the specification in limiting the term to hierarchies contained in a “structured  
25 medical dictionary, such as MedDRA.” *Id.* Moreover, DrugLogic contends, the specification  
26 supports DrugLogic’s broader construction of “hierarchy.” *Id.* First, DrugLogic quotes the  
27 following passage, which it argues is a description of one version of the claimed hierarchy:  
28

[W]hen a box on a table or in a matrix or a hyperlink is selected, the case listing is generated. When a user clicks on any of the numbers, he/she is provided with a listing of each of the cases corresponding to that link. . . Additionally, if a user wishes to learn the details of a specific case, he/she can click on the case ID number of any specific case on the correlation details screen. This Case Details screen provides detailed information on each specific case.

*Id.* at 16 (quoting '091 patent, col. 24, ll. 32-59).

Second, DrugLogic notes that the specification states that “[t]he ability to browse statistics, up and down a hierarchy . . . is important to keeping risk assessment hypothesis setting and testing within a short period of time.” *Id.* at 16 (quoting '091 patent, col. 18, ll. 18-21). This ability is depicted in at least three places in Figure 1 of the '091 patent, DrugLogic contends. *Id.* In particular, DrugLogic argues that in Figure 1 “the claimed hierarchy is depicted, showing (1) a profile or results of a statistical calculation, followed by drilling down to (2) the case list related to the calculation, followed by drilling down to (3) the case details for the cases in the list.” *Id.*

DrugLogic also cites to

the fact that the case details themselves can be structured to be expandable for particular dimensions.

*Id.* (citing '091 patent, col. 24, ll. 59-63).

According to DrugLogic, “[t]he specification provides that one of these dimensions – reaction time – is *preferably* structured in accordance with a structured hierarchical dictionary/thesaurus, such as MedDRA.” *Id.* at 17 (emphasis supplied by DrugLogic). Specifically, the specification provides as follows:

For certain dimensions, for example reactions, the hierarchy of the dimension can be selected to change the billboard and detailed views. In the case of reactions, MedDRA contains a five level hierarchy. Other dictionaries use two to four levels. The present invention accommodates the full range of hierarchies.

*Id.* (quoting '091 patent, col. 7, ll. 48-54). “Thus,” DrugLogic asserts, “while the specification discusses that the reaction dimension can be arranged in accordance with a hierarchical structured medical dictionary, such as MedDRA, that is not the claimed hierarchy.” *Id.*

DrugLogic also contends that Oracle’s construction makes no sense in the context of the claims themselves. *Id.* at 17. In particular, DrugLogic points to the limitation in claims 1 and 8 requiring that “a last one of the hyperlinks in the up and down hierarchy link[] to a previously-stored case describing adverse effects resulting from the use of the at least one drug [substance] of

1 interest.” *Id.* (quoting claims 1 & 8). The MedDRA hierarchy, however, does not contain any  
2 patient information because it is simply a medical dictionary/thesaurus. *Id.* Further, the last level of  
3 the MedDRA hierarchy is not a previously-stored case; instead, it is the preferred term for a  
4 particular reaction. *Id.* As a result, DrugLogic asserts, if the claimed hierarchy were limited to the  
5 MedDRA hierarchy, as Oracle proposes, it would not satisfy the requirement that the last hyperlink  
6 in the hierarchy is a previously stored case. *Id.*

7 Finally, DrugLogic relies on the prosecution history in support of its proposed construction.  
8 *Id.* at 18. In particular, it points to arguments made by the applicant during the application process  
9 emphasizing the importance of the ability to use a hyperlink within the hierarchy to display the  
10 underlying patient case date. *Id.* at 18. In particular, the applicant, Victor Gogolak, argued as  
11 follows:

12 One of the features that provides significant improvement over any prior art adverse drug  
13 effects research systems or other methodologies is the association of the analytical results  
14 and underlying data with hyperlinks, which are respectively associated with different places  
15 in a hierarchy....The last portion of the amended claim [“a last one of the hyperlinks in the  
up and down hierarchy linking to a previously stored case”] is particularly important in that  
no matter what type of statistics a user of the system may be viewing, the fundamental or  
underlying data, namely, a particular “case” is always available for display.

16 *Id.*, Ex. 5 at 11. He further argued that “there is absolutely nothing in [the prior art] that discloses or  
17 even suggests the use of hyperlinks in a hierarchical fashion in which a last one of the hyperlinks  
18 points to a previously stored case describing adverse effects resulting from a given drug of interest.”  
19 *Id.*, Ex. 5 at 12.

20 Oracle argues that DrugLogic’s position is incorrect because it fails to take into account the  
21 intrinsic evidence, instead relying on “generic extrinsic dictionary definitions of the term  
22 ‘hierarchy,’ untethered to the context of the ‘091 patent.” Oracle Responsive Brief (‘091 patent) at  
23 11. Pointing to its expert’s testimony that at the time of the invention the term “up and down  
24 hierarchy” had no ordinary meaning, Oracle contends the meaning of the term would have been  
25 drawn from the claims and specification, which support Oracle’s proposed construction. *Id.* at 11-12  
26 (citing Jolley Decl., ¶¶ 22-24).

27 With respect to claim language, Oracle cites to the language in claims 1 and 8 specifying that  
28 “analytical drill down” is performed by “selectively selecting successive hyperlinks,” and that those

1 hyperlinks “respectively correspond[] to places in an up and down hierarchy.” *Id.* at 12. This  
2 language makes clear, according to Oracle, that “analytical drill down” occurs along the “up and  
3 down hierarchy.” *Id.* Oracle further contends that “[t]his corresponds with the ’091 specification’s  
4 definition of ‘analytical drill down’ as occurring at different levels of the MedDRA hierarchy.” *Id.*  
5 Thus, Oracle asserts, the “up and down hierarchy” and the MedDRA hierarchy are “one and the  
6 same” and therefore, “places in an up and down hierarchy” should be construed as “levels of a  
7 structured medical dictionary, such as MedDRA.” *Id.*

8 Oracle argues that the specification also supports this conclusion because it describes in  
9 detail how the invention of the ’091 patent makes use of the MedDRA hierarchy. *Id.* For example,  
10 the specification describes Figure 7 as follows:

11 By utilizing the pull down menu, a user can choose among multiple different levels of  
12 MedDRA. . . . In FIG. 7, a user has chosen the HLT option. The window in the pull-down  
13 menu indicates that there are 256 HLTs out of the total of 1495 HLTs in the current version  
14 of MedDRA. The Reactions Table 702 shows the Top 10 HLTs of the 256.

15 *Id.* (quoting ’091 patent col. 17, l. 64 - col. 18, l. 23) (emphasis added)). Oracle notes that at the end  
16 of this description of “the invention’s MedDRA functionality,” the specification states as follows:

17 The ability to browse statistics, up and down a hierarchy, and within real time, is important  
18 to keeping risk assessment hypothesis setting and testing within a short period of time.

19 *Id.* (quoting ’091 patent, col. 18, ll. 18-20). This is the only place in the patent that the term “up and  
20 down hierarchy” appears, and to the extent it is used in connection with the invention’s use of  
21 MedDRA, Oracle contends, it supports the conclusion that the “up-and-down hierarchy” described  
22 in the ’091 patent “is a MedDRA-like hierarchy” and therefore, “places in an up and down  
23 hierarchy” means “levels of a structured medical dictionary, such as MedDRA.” *Id.* at 12-13.

24 Oracle rejects DrugLogic’s position, based on extrinsic evidence, that a hierarchy means  
25 simply, “things ranked one above another.” *Id.* at 13. According to Oracle, many of the purported  
26 examples of hierarchies in the specification that are offered by DrugLogic are not described as  
27 hierarchies at all. *Id.* For example, Oracle points out that Figure 1, which DrugLogic cites as an  
28 example of a hierarchy, is described in the specification as a “chart indicating the page flow of the  
present invention.” *Id.* (citing ’091 patent, col. 7, ll. 58-60). Similarly, the version of the invention

1 described in column 24 at lines 32-59, on which DrugLogic relies in support of its proposed  
2 construction, does not use the word “hierarchy.” *Id.* According to Oracle, the word “hierarchy” is  
3 used only to refer to the hierarchy of MedDRA or other structured medical dictionaries. *Id.* (citing  
4 ‘091 patent, col. 14, ll. 47-51 (“MedDRA hierarchy Group”); col. 17, ll. 48-53 (“In the case of  
5 reactions, MedDRA contains a five level hierarchy.”); col. 18, ll.18-22 (“The ability to browse  
6 statistics, up and down a hierarchy”) (discussed in detail above); col. 20, ll. 1-2 (“The filter is based  
7 on the MedDRA hierarchy and begins at the SOC level.”); col. 20, ll.12-19 (“For displayed  
8 MedDRA leads, preferably a tree is used. When it is collapsed, an open box preferably means no  
9 selections lower in the hierarchy have been identified . . . .”)).

10 Oracle also rejects DrugLogic’s argument that “the up-and-down hierarchy” cannot be  
11 limited to a MedDRA-like hierarchy because of the language of claims 1 and 8 relating to “a last one  
12 of the hyperlinks . . . linking to a previously-stored case.” *Id.* at 13-14. According to Oracle, this  
13 argument is based on a misreading of the claim language, which does “not require that the lowest  
14 level of the hierarchy *be* the previously-stored case; they require only that ‘a last one of the  
15 hyperlinks in the up and down hierarchy *link[]* to a previously stored case describing adverse effects  
16 resulting from the use of the at least one drug of interest.” *Id.* (quoting claims 1 & 8)(emphasis in  
17 Oracle’s brief). Oracle offers the following example to illustrate this point:

18 For example, imagine a user viewing statistics related to the impact of a particular drug on  
19 the Ear and Labyrinth Disorders SOC. That user could click hyperlinks along the “up and  
20 down hierarchy” of MedDRA to view statistics related to the impact of that drug on the  
21 “painful sensitiveness to sound” LLT. On the LLT page, representing statistics related to a  
22 “painful sensitiveness to sound,” there could be an additional hyperlink linking to a  
previously stored case in which a patient suffered “painful sensitiveness to sound.” That  
hyperlink would be “a last one of the hyperlinks in the up and down hierarchy,” and it would  
“link[] to a previously stored case,” as required by the claims.

23 *Id.* at 14. Oracle contends that this is how DrugLogic’s Qscan product operates, as is explained by  
24 DrugLogic in a Qscan product demo. *Id.* (citing Von Der Ahe Decl., Ex. M). Because DrugLogic  
25 admits that Qscan is an embodiment of the ‘091 patent, Oracle argues, this evidence supports  
26 Oracle’s proposed construction. *Id.* at 14-15.

27 In its reply brief, DrugLogic argues that Oracle has mischaracterized the ‘091 specification  
28 by failing to acknowledge the fact that it references not just the MedDRA hierarchy but many

1 hierarchies, including hierarchies that pertain to dimensions such as reactions, concomitant drugs,  
2 demographics, report dates and outcomes. DrugLogic's Reply Brief ('091 patent) at 7 (citing '091  
3 patent, col. 17, ll. 52-53 ("The present invention accommodates the full range of hierarchies."); col.  
4 24, ll. 59-60) ("If these details are structured, all features of the invention are expandable to that  
5 dimension.")). DrugLogic contends that Oracle's expert conceded this point. *Id.* (citing  
6 DrugLogic's Reply Brief ('091 patent), Ex. A (Jolley Depo.)). DrugLogic further contends that its  
7 position is supported by disclosure in the specification making clear that the user can build his or her  
8 own hierarchies. *Id.* (citing '091 patent, col. 14, ll. 16-20 ("[i]n addition, the invention provides the  
9 ability to develop specific other taxonomies, such as a 'super generic' including all salts of a drug, or  
10 a sub-brand, for example distinguishing between once a day version of a drug from once a week  
11 version of a drug"); col. 15, ll. 40-51 (describing how a user can search using various categories,  
12 including "custom-defined categories"); col. 16, ll. 1-2 (reference to "custom-designed categories");  
13 col. 17, ll. 55-56 (same); col. 20, ll. 35-53 (describing filters that can be included in various  
14 embodiments of the invention, including filters for dimensions such as demographics, drug birth date  
15 and outcomes, and noting that "if a custom seriousness set is defined, this dimension will be user  
16 definable"). Oracle's proposed construction would improperly exclude these disclosed hierarchies,  
17 DrugLogic argues. *Id.* In contrast, DrugLogic asserts, its own proposed construction would include  
18 all of the hierarchies disclosed in the specification and comports with the ordinary meaning of the  
19 word "hierarchy," which Oracle's expert conceded means "something with layers" or "some entity  
20 with levels." *Id.* at 8 n. 12 & Ex. A (Jolley Dep.) at 33-35.

21 Similarly, DrugLogic argues that many of the references to the MedDRA hierarchy are  
22 offered as examples, further supporting the conclusion that the inventor did not limit his invention to  
23 the MedDRA hierarchy. *Id.* at 8 (citing '091 patent, col. 17, ll. 48-51 ("[f]or certain dimensions, for  
24 example reactions, the hierarchy of the dimension can be selected to change the billboard and  
25 detailed views. In the case of reactions, MedDRA contains a five level hierarchy"); col. 14, ll. 40-51  
26 (identifying "an example" of the results of a saved filter showing a drug's reactions); col. 17, ll.  
27 57-61 ("With regard to the Reactions dimension, the profiled component of the present invention  
28 preferably shows reactions to the drug that is being queried"); col. 19, l. 66 - col. 20, l. 2 (discussing

1 Fig. 12's depiction of a filter based on the MedDRA hierarchy as “[a]n exemplary filter”).

2 DrugLogic challenges Oracle's argument that the MedDRA hierarchy satisfies the  
3 requirement of claims 1 and 8 that the last hyperlink must link to a case, arguing that this  
4 requirement is not satisfied under Oracle's construction because the specification only describes  
5 MedDRA as a means to filter data and display statistical results. *Id.* at 8-9. Further, DrugLogic  
6 asserts, Oracle's reliance on DrugLogic's Qscan product is misplaced. First, because that product is  
7 only an embodiment of the invention, DrugLogic argues, it cannot form the basis of any claim  
8 construction. *Id.* at 9 n. 15 (*citing Int'l Vision Corp. v. Crown Metal Manufacturing Co.*, 991 F.2d  
9 768, 771-772 (Fed. Cir. 1993)). Second, DrugLogic contends that “clicking on the last hyperlink in  
10 the MedDRA hierarchy in Qscan will only display the statistical results for that level of MedDRA  
11 hierarchy.” *Id.* at 9. According to DrugLogic, “[i]t is not until the user clicks on the hyperlink for  
12 the statistical result (a hyperlink that is not *in* the MedDRA hierarchy) that the hierarchy called for  
13 by the claim is implicated.” *Id.*

14 DrugLogic contends that its proposed construction is consistent with the specification's  
15 description of how the hierarchy in the invention can be used, which “describes how a user can click  
16 on a hyperlink associated with a statistical analysis to get to a case list and can then click on another  
17 hyperlink associated with that case list to be taken to a previously stored case.” *Id.* (citing '091  
18 patent, col. 24, ll. 32-50). According to DrugLogic “this hierarchy of data is the hierarchy that is  
19 contemplated by the ‘wherein’ clause as it describes how the user can click on successive hyperlinks  
20 to go to the case details.” *Id.* DrugLogic further contends that this hierarchy is described repeatedly  
21 throughout the specification. *Id.* (citing '091 patent, Fig. 1 at reference numerals 105-107, 108-110  
22 and 112-114; col. 24, ll. 32-50; col. 9, ll.10-29; and col. 10, ll. 4-5).

## 23                   ii.        Analysis

24                   As discussed above, a claim term should be given its ordinary meaning as it would be  
25 understood by a person skilled in the art at the time of the invention who has read the specification  
26 and is familiar with the prosecution history. Although Oracle challenges DrugLogic's reliance on  
27 extrinsic evidence for its definition of the word “hierarchy,” the parties do not disagree in any

1 meaningful way about the meaning of that word, standing on its own.<sup>4</sup> The more difficult question  
2 is whether the claim term “hyperlinks . . . corresponding to places in an up and down hierarchy”  
3 refers to a more limited set of hierarchies. Based on the disclosure in the specification, the Court  
4 concludes that this claim term requires construction because the generic meaning of “hierarchy” is  
5 broader than the meaning of “up and down hierarchy” in the ‘091 claims. Further, the Court agrees  
6 with Oracle that the “up and down hierarchy” refers to MedDRA or some other structured medical  
7 dictionary.

8 Read together, the claims and the specification support Oracle’s proposed construction. As  
9 to the claims, the language of the Wherein Clause, in claims 1 and 8, supports the conclusion that  
10 “analytical drill down” occurs along the “up and down hierarchy,” providing that “analytical drill  
11 down” is performed by “selectively selecting successive hyperlinks” that “correspond[] to places in  
12 an up and down hierarchy.” Thus, the description of analytical drill down in the specification sheds  
13 light on the meaning of “up and down hierarchy.” The Court finds particularly significant the  
14 passage of the specification found at col. 17, l. 34 - col. 18, l. 22. In that passage, the patentees  
15 explain that “[t]he profile feature of the present invention is used to display statistics that describe  
16 the effects of the drug in multiple dimensions.” ‘091 patent, col. 17, ll. 34-35. The specification  
17 offers as an example “reactions,” noting that in MedDRA the hierarchy contains five levels for  
18 reactions. ‘091 patent, col. 17, ll. 50-51. It goes on to state that “[o]ther dictionaries contain two to  
19 four levels” and that the invention “accommodates the full range of hierarchies.” ‘091 patent, col  
20 17, ll. 51-53. Finally, the passage states that this “ability to browse statistics, *up and down a*  
21 *hierarchy*, and within real time, is important to keeping risk assessment hypothesis setting and  
22 testing within a short period of time.” ‘091 patent, col. 18, ll. 18-20 (emphasis added). This passage  
23 supports the conclusion that an “up and down hierarchy” is a structured medical dictionary, of which  
24 MeDRA is one example.

25 Although DrugLogic cites to disclosure in the specification that the user can define his or her  
26 own classes or dimensions, it does not point to any discussion in the specification indicating that

27 

---

28 <sup>4</sup>As stated above, DrugLogic contends the word means “a system of . . . things ranked one above  
the other,” while Oracle’s expert testified that a hierarchy is “something with layers.”

1 these classes or dimensions would themselves be components of the “up and down hierarchy.” Nor  
2 is the Court persuaded by DrugLogic’s argument that Figure 1 of the ‘091 patent provides examples  
3 of “up and down hierarchies.” Although Figure 1 illustrates how the invention allows the user to  
4 “drill down” to obtain case details, the description of this figure does not identify these steps as  
5 being part of the “up and down hierarchy” described in the claims. *See* ‘091 patent, col. 8, l. 62 -  
6 col. 9, l. 50. Rather, the specification describes Figure 1 as a “chart indicating the page flow of the  
7 present invention.” ‘091 patent, col. 7, ll. 58-60. Similarly, the passage found at col. 24, ll. 32-59,  
8 which DrugLogic contends describes a version of the “up and down hierarchy,” does not contain the  
9 word “hierarchy.”

10 Further, the Court rejects DrugLogic’s contention that MedDRA and other structured  
11 medical dictionaries do not satisfy the requirement in claims 1 and 8 that the last hyperlink in the  
12 hierarchy must link to a previously stored case. Rather, the Court finds that Oracle is correct in its  
13 assertion that the last hyperlink in the up and down hierarchy of MedDRA or other dictionaries can  
14 link to previously stored cases and thus satisfy this limitation. As the Court finds nothing in the  
15 specification that suggests that the case information must be the bottom level of the “up and down  
16 hierarchy,” the Court rejects DrugLogic’s position.

17 Accordingly, the Court construes “hyperlinks . . . corresponding to places in an up and down  
18 hierarchy” as follows: “such links . . . corresponding to different levels of a structured medical  
19 dictionary, such as MedDRA.”

20  
21  
22  
23  
24  
25  
26  
27  
28

### i. The Parties' Positions

DrugLogic's Proposed Construction	Oracle's Proposed Construction
<p>“generating hyperlinks corresponding to subsets of the information reflecting the risks of adverse effects and the statistical analysis”</p>	<p><b>Initial:</b> “creating a plurality of links within web pages for some of the previously stored information and some of the results of the statistical analysis such that clicking on the information or results causes a user to jump to another web page”</p> <p><b>Modified:</b> “creating a plurality of links within web pages for some of the previously stored information and some of the results of the statistical analysis such that clicking on the information or results causes a user to jump to another place in the same web page or to an entirely different web page”</p>

DrugLogic’s proposed construction of “associating respective hyperlinks with a plurality of portions of such data and analysis” is “generating hyperlinks corresponding to subsets of the information reflecting the risks of adverse effects and the statistical analysis.” According to DrugLogic, the plain meaning of the word “associate” supports its proposed construction. DrugLogic Opening Brief (‘091 patent) at 13-14. DrugLogic quotes the following dictionary definition of the word “associate”: “to join or connect together; to bring together or into relationship in any of various intangible ways . . .” *Id.*, Ex. 6 (print-out from on-line version of Merriam-Webster Dictionary). Thus, DrugLogic contends, “[i]n the context of the claim, associate means to connect two pieces of information (whether, for example, data regarding adverse events or the statistical analysis) such that the user can get from one piece of information to another.” *Id.* at 14.

DrugLogic also points to the following passage in the specification in support of its proposed construction:

Another important aspect of the web-based analysis . . . is the ability to associate hyperlinks with each piece of data. For example, within the application, it is possible to link each number, name, entry, and selectable point with additional information.

1        *Id.* (quoting ‘091 patent, col. 13, ll. 36-42). According to DrugLogic, this passage indicates that  
2        “data can be linked to other data, results can be linked to data, data can be linked to results, results  
3        can be linked to results, etc.” *Id.*

4        DrugLogic argues that Oracle’s proposed construction<sup>5</sup> is incorrect for two reasons. First, it  
5        contends that Oracle’s construction “is not based on the plain meaning of the words of the claim or  
6        the specification [because] [a]ssociating hyperlinks with the data and analysis simply means that the  
7        data and analysis are related to each other or other information via a hyperlink generated by the  
8        system.” *Id.* at 13. Second, DrugLogic argues that Oracle’s proposed construction is incorrect to the  
9        extent it requires that the hyperlinks link to a separate web page. *Id.* at 14. DrugLogic contends that  
10        this language also applies to hyperlinks that link to another location on the same web page. *Id.*

11        According to Oracle, the main dispute between the parties is “whether ‘associating  
12        hyperlinks’ with ‘portions of [] data and analysis’ means making those ‘portions of []data and  
13        analysis *into* clickable hyperlinks’ (Oracle’s proposed construction), or whether it means something  
14        much more vague: ‘generating hyperlinks corresponding to subsets of information reflecting the risk  
15        of adverse effects and the statistical analysis.’ (DrugLogic’s proposed construction.)” Oracle  
16        Responsive Brief (‘091 patent) at 15.

17        Oracle argues that its proposed construction is supported by the specification, citing the same  
18        passage upon which DrugLogic relies, col. 13 at lines 37-42 (quoted above). *Id.* at 16. According to  
19        Oracle, this passage means that “to ‘associate’ a hyperlink with a piece of data, in this patent, means  
20        to ‘link’ that piece of data with additional information by turning the piece of data into a hyperlink.”  
21        *Id.* Oracle also points to two figures that it contends illustrate such hyperlinks, Figures 13 and 19.  
22        Figure 13 depicts “an exemplary screen presenting the results of a correlated search.” ‘091 patent,  
23        col. 21, ll. 23-24. The search results are ranked according to the strength of the correlation and “a  
24        user is preferably presented hyperlinks comprising all of the numbers in the Rank column.” ‘091  
25        patent, col. 21, l. 67 - col. 22, l. 2. “These hyperlinks provide a link to individual case lists.” ‘091  
26        patent, col. 22, ll. 3-5. “Figure 19 is the tabular presentation of the proportional analysis results.”

27        <sup>5</sup>At the time DrugLogic filed its opening brief, Oracle’s proposed construction was the initial  
28        construction quoted above.

1 ‘091 patent, col. 23, ll. 53-54. Two of the columns show the correlated terms, while a third shows  
2 the reaction “count.” ‘091 patent, col. 31, ll. 54-62. Two additional columns list the “expected  
3 reaction count” and the “relative ratio.” *Id.* The specification explains that the reaction count  
4 numbers are “hyperlinked to the case-list.” ‘091 patent, col. 23, ll. 65-66. Finally, Oracle points to  
5 the statement in the specification that “if a user wishes to learn the details of a specific case, he/she  
6 can click on the case ID number of any specific case on the correlation details screen.” Oracle’s  
7 Responsive Brief (‘091 patent) at 16 (citing ‘091 patent, col. 24, ll. 46-48).

8 Oracle also cites the prosecution history in support of its proposed construction, pointing to  
9 the following argument made by Mr. Gogolak in support of patentability:

10 One of the features that provides significant improvement over any prior art . . . is the  
11 association of analytical results and underlying data with hyperlinks, which are respectively  
associated with different places in a hierarchy.

12 Von Der Ahe Decl., Ex. K at 11. According to Oracle, this “explains that analytical results and  
13 underlying data are made into hyperlinks, and that those hyperlinks, in turn, point to different places  
14 in a hierarchy.” Oracle’s Responsive Brief (‘091 patent) at 16.

15 Oracle argues that DrugLogic’s proposed construction makes no sense because it reasons,  
16 based on the definition of “associate,” that “associating . . . hyperlinks with . . . portions of such data  
17 and analysis” means “to join or connect two pieces of information . . . such that the user can get from  
18 one piece of information to another.” *Id.* (quoting DrugLogic’s Opening Brief (‘091 patent) at 14).  
According to Oracle, this reasoning does not follow from the language of the claims because “it is  
20 the *hyperlink* that is associated with a piece of information, not pieces of information that are being  
21 associated to one another.” *Id.*

22 In response to DrugLogic’s contention that Oracle’s proposed construction incorrectly  
23 requires that the hyperlink take a user to a different web page, Oracle modifies its proposed  
24 construction to allow for hyperlinks that permit the user to jump to a different location on the *same*  
25 page, proposing the following construction:

26 creating a plurality of links within web pages for some of the previously stored information  
27 and some of the results of the statistical analysis such that clicking on the information or  
results causes a user to jump to another place in the same web page or to an entirely different  
web page.

28

1 *Id.* at 17. Oracle contends that this proposed construction is consistent with the parties' agreement  
2 that "such data and analysis" shall be construed to mean "previously stored information reflecting  
3 occurrences of adverse events and results of the statistical analysis." *Id.* n. 5 (citing Von Der Ahe  
4 Decl., Ex. B (Amended Joint Claim Construction and Prehearing Statement) at 3).

5 In its reply brief, DrugLogic argues that there is no support for limiting this claim term to a  
6 particular method of "associating . . . hyperlinks . . . with . . . data and analysis." DrugLogic's Reply  
7 Brief ('091 patent) at 5-6. Rather, "so long as both the anchor and target pages include portions of  
8 the data and analysis, then such portions of data and analysis are 'associated' with the hyperlink."  
9 *Id.* at 6. According to DrugLogic, Oracle's proposed construction impermissibly adds a limitation  
10 that is not found in either the intrinsic or extrinsic evidence.

11 At oral argument, DrugLogic acknowledged that one way to satisfy this claim term is to turn  
12 the data or analysis itself into hyperlinks. It argued, however, that the claim term is not *limited* to  
13 this manner of associating hyperlinks with data or analysis. In support of this position, DrugLogic  
14 argued, for the first time, that Figure 13 (cited in Oracle's responsive claim construction brief) does  
15 not support Oracle's proposed construction but instead reflects an "association" of a hyperlink to  
16 data or analysis that is *not* accomplished by turning the actual data or analysis into a hyperlink. In  
17 particular, DrugLogic argues that the rankings in the Rank column in that figure are not "analysis or  
18 data." It is these numbers, however, that are turned into hyperlinks in order to permit a user to  
19 obtain stored information about the underlying cases. Similarly, DrugLogic asserted (again, for the  
20 first time), Figure 14 depicts an "association" of hyperlinks to data or analysis in which the  
21 association is not achieved by turning the data or analysis itself into hyperlinks. Rather, according  
22 to DrugLogic, the Case Id. numbers are turned into hyperlinks. Oracle countered that DrugLogic's  
23 position was contradicted by the passage in the specification quoted above, found at col. 13, ll. 38-41  
24 of the '091 patent ("For example, within the application, it is possible to link each number, name,  
25 entry and selectable point with additional information.")

26  
27  
28

## ii. Analysis

The dispute as to this claim term turns on the nature of the claimed “association” between the “hyperlink” and “such data and analysis.” Is the data and analysis that is referred to in the claim as “such data and analysis” actually turned into a hyperlink (as Oracle contends) or can the hyperlink be “associated” with that data and analysis in other ways as well (as DrugLogic contends)? Although the words of the claim itself are ambiguous as to the meaning of the word “associate,” the Court finds that the specification and prosecution history support Oracle’s position that this claim term requires that the data and analysis must be turned into hyperlinks.

First, in the specification, the inventors describe the ability of the invention to associate hyperlinks “with each piece of data” and offer as examples the ability of the invention to “link each number, name, entry, and selectable point with additional information.” ‘091 patent, col. 13, ll. 36-42. In other words, the “data” itself is “link[ed]” to other information; moreover, the inventors indicate that “number[s], name[s], entr[ies] and selectable point[s] are all examples of “data.” Further, Figures 13 and 19 depict data items and analysis that have been made into hyperlinks. In particular, in Figure 13 the numbers that indicate Rank are hyperlinks, and in Figure 19, the reaction count numbers are turned into hyperlinks.

Second, the arguments made during the prosecution history support the conclusion that the words “associating . . . hyperlinks with . . . such data and analysis” mean turning the data and analysis into hyperlinks. In particular, the inventor stated that “[o]ne of the features that provides significant improvement over any prior art . . . is the association of analytical results and underlying data with hyperlinks, which are respectively associated with different places in a hierarchy.” *See Von Der Ahe Decl.*, Ex. K at 11.

The Court is not persuaded by DrugLogic’s argument, raised for the first time at the claim construction hearing, that Figures 13 and 14 support a contrary result to the extent that the Rank numbers in Figure 13 and the Case Ids. in Figure 14 are turned into hyperlinks.<sup>6</sup> The premise of

<sup>6</sup>This argument should have been raised in DrugLogic's opening or reply claim construction briefs. DrugLogic's failure to raise this argument in its briefs is particularly troubling because Oracle expressly asserted in its responsive claim construction brief that Figure 13 supported its proposed

1 DrugLogic's argument is that Rank numbers and Case Ids. are not "data" or "analysis," and  
2 therefore, to the extent that these figures illustrates the association of hyperlinks with "such data and  
3 analysis,"<sup>7</sup> that claim term cannot be limited to a method whereby the data and analysis is *itself*  
4 turned into hyperlinks. DrugLogic relies in part on the parties' agreement that "such data and  
5 analysis" means "previously stored information reflecting occurrences of adverse events and results  
6 of the statistical analysis." Rank numbers and Case Ids. do not fall within this definition, DrugLogic  
7 asserts, because they do not reflect occurrences of adverse events and results of statistical analysis.  
8 The language of the parties' construction of "such data and analysis" is itself ambiguous, however.  
9 For example, the Case Id.s might be considered part of the stored information reflecting occurrences  
10 of adverse events because they correspond to a data set reflecting such occurrences. Further, the  
11 Rank numbers in Figure 13 are essentially analysis in that they rank the scores that are associated  
12 with pairs of terms. At oral argument, DrugLogic acknowledged that the "score" was the "analysis."  
13 Rather than engage in an exercise of trying to parse the meaning of the words used by the parties in  
14 their stipulated construction, the Court finds that it is sufficient that that construction can be  
15 reconciled with the Court's construction of the claim term as a whole, based on its reading of the  
16 claims in light of the specification and prosecution history.

17 Accordingly, the Court adopts Oracle's proposed construction. The term "associating  
18 respective hyperlinks with a plurality of portions of such data and analysis" is construed as follows:  
19 "creating a plurality of links within web pages for some of the previously stored information and  
20 some of the results of the statistical analysis such that clicking on the information or results causes a  
21 user to jump to another place in the same web page or to an entirely different web page."

22  
23  
24  
25 construction. DrugLogic did not respond to that argument in its reply brief. On that basis, DrugLogic  
26 arguably waived this argument. Nevertheless, in the interest of construing this claim term in a manner  
27 that is consistent with its usage in the specification, the Court considers the argument on the merits.  
28

<sup>7</sup>At oral argument, the parties did not dispute that these figures provide examples of the claimed hyperlinks.

## 2. Other Disputed Claim Terms in Claims 1 and 8

a. "permitting the at least one remote user to analyze safety issues"

DrugLogic's Proposed Construction	Oracle's Proposed Construction
“permitting the at least one remote user to use statistical analysis to study safety issues”	“permitting the at least one remote user to run a statistical analysis that finds ‘signals’ such as anomalies in a random population, changes against a known background, or coherent targets in a noise background”

### i. The Parties' Positions

9       According to DrugLogic, the parties agree that this term means “permitting the at least one  
10 remote user to use statistical analysis” but disagree as to the meaning of the phrase “to analyze  
11 safety issues.” DrugLogic’s Opening Brief (‘091 patent) at 12. DrugLogic contends that Oracle’s  
12 proposed construction improperly limits the way safety issues must be analyzed, namely, by  
13 requiring that safety issues must be analyzed by “finding signals.” *Id.* This approach should be  
14 rejected, DrugLogic asserts, because it violates the doctrine of claim differentiation, which provides  
15 that where a particular limitation is included in a dependent claim, a presumption arises that that  
16 limitation is not found in the independent claim. *Id.* (citing *Acumed LLC v. Stryker Corp.*, 483 F.3d  
17 800, 806 (Fed. Cir. 2007)). Here, DrugLogic points out, the limitation proposed by Oracle is found  
18 in dependent claims 15 and 16, which depend from claims 1 and 8, respectively. *Id.* In fact,  
19 DrugLogic contends, this additional limitation is the “only meaningful difference” between  
20 independent claims 1 and 8 and dependent claims 15 and 16. *Id.* DrugLogic further asserts that  
21 Oracle’s violation of the doctrine of claim differentiation is “particularly glaring because the  
22 meaning of the phrase ‘to analyze safety issues’ is readily apparent.” *Id.* That meaning is evident,  
23 DrugLogic argues, from dictionary definitions of the word “analyze.” *Id.* at 12-13 and Ex. 6  
24 (Excerpts from Merriam-Webster’s Online Dictionary, [www.merriam - webster.com](http://www.merriam-webster.com) (2012))  
25 (defining “analyze” as “to study...the nature and relationship of the parts of by analysis”); Ex. 7  
26 (excerpt from Dictionary.com, [www.dictionary.reference .com](http://www.dictionary.reference.com) (2012)) (defining “analyze” as “(2) to

1 examine critically...; (3) to examine carefully and in detail so as to identify causes, key factors,  
2 possible results, etc.; (4) to subject to mathematical . . . analysis”).

3 DrugLogic acknowledges that the specification of the ‘091 patent “discusses that the  
4 invention assists safety groups with ‘determining “signals” that indicate a relationship among  
5 adverse reactions, demographics, and other elements such as outcomes.’” *Id.* at 13 (citing ‘091  
6 patent, col. 6, ll. 11-35). This passage, however, does not support Oracle’s proposed construction,  
7 DrugLogic argues, because “[t]he fact that a patent asserts that an invention achieves several  
8 objectives does not require that each of the claims be construed as limited to structures that are  
9 capable of achieving all of the objectives.” *Id.* (quoting *Liebel-Flarsheim Co. v. Medrad, Inc.*, 358  
10 F.3d 898, 908 (Fed. Cir. 2004)).

11 Oracle responds that the presumption of claim differentiation is rebuttable and that it is  
12 rebutted here. Oracle Responsive Brief (‘091 patent) at 17 -18 (citing *Marine Polymer Techs., Inc.*  
13 v. *HemCon, Inc.*, 672 F.3d 1350, 1359 (Fed. Cir. 2012)). In particular, Oracle points to the  
14 following passage in the specification, which Oracle contends expressly limits the scope of the  
15 invention:

16 The analysis provided by the system and method of the present invention finds “signals”  
17 such as anomalies in a random population, a change against a known background, or a  
coherent target in a noise background.

18 *Id.* (quoting ‘091 patent, col. 20, ll. 54-57). According to Oracle, this language “does not merely  
19 describe a preferred embodiment of the invention – it describes *the* ‘present invention.’” *Id.* at 18  
20 (emphasis in original). Therefore, Oracle contends, this feature must be included in the Court’s  
21 construction of this claim term. *Id.* (citing *Netcraft Corp. v. eBay, Inc.*, 549 F.3d 1394, 1398 (Fed.  
22 Cir. 2008); *Verizon Services Corp. v. Vonage Holdings Corp.*, 503 F.3d 1295, 1308 (Fed. Cir.  
23 2007)).

24 DrugLogic argues in its reply brief that the language in the specification cited by Oracle  
25 “merely references one aspect or advantage” of the invention and the Court must give the claim term  
26 the full range of its ordinary meaning. DrugLogic’s Reply Brief (‘091 patent) at 5 (citing *Kim v.*  
27 *ConAgra Foods, Inc.*, 465 F.3d 1312, 1319 (Fed. Cir. 2006); *Howmedica Osteonics Corp. v. Wright*  
28 *Med. Tech., Inc.*, 540 F.3d 1337, 1345 (Fed. Cir. 2008)). DrugLogic reiterates its position that the

1 doctrine of claim differentiation supports its proposed construction, citing this Court's decision in  
2 *Augme Techs., Inc. v. Yahoo!, Inc.*, 2011 U.S. Dist. LEXIS 109886 at \*48-51 (N.D. Cal. Sept. 27,  
3 2011).

4 **ii. Analysis**

5 The question facing the Court is whether the language in the specification describing the  
6 "present invention" limits the meaning of the phrase "to analyze safety issues" in claims 1 and 8,  
7 even though such a construction would give rise to a result that is generally disfavored in claim  
8 construction, namely, that claims 15 and 16 would claim essentially the same subject matter as  
9 claims 1 and 8, respectively. The Court concludes that it does.

10 The doctrine of claim differentiation "stems from 'the common sense notion that different  
11 words or phrases used in separate claims are presumed to indicate that the claims have different  
12 meanings and scope.'" *Seachange Intern., Inc. v. C-COR, Inc.*, 413 F.3d 1361, 1368 (Fed. Cir.  
13 2005) (quoting *Karlin Tech. Inc. v. Surgical Dynamics, Inc.*, 177 F.3d 968, 971-72 (Fed. Cir. 1999)).  
14 In *Seachange*, the Federal Circuit explained that the doctrine is "at its strongest" where, as here,  
15 "'the limitation sought to be "read into" an independent claim already appears in a dependent  
16 claim.'" *Id.* at 1369 (quoting *Liebel-Flarsheim Co. v. Medrad, Inc.*, 358 F.3d 898, 910  
17 (Fed.Cir.2004)). The doctrine only creates a presumption, however, and is not "'a hard and fast rule  
18 of construction.'" *Id.* (quoting *Kraft Foods, Inc. v. Int'l Trading Co.*, 203 F.3d 1362, 1368 (Fed. Cir.  
19 2000)). The doctrine of claim differentiation cannot "'broaden claims beyond their correct scope,  
20 determined in light of the specification and the prosecution history and any relevant extrinsic  
21 evidence. . . .'" *Id.* (quoting *Multiform Desiccants, Inc. v. Medzam, Ltd.*, 133 F.3d 1473, 1480  
22 (Fed.Cir.1998)). As a result, "claims that are written in different words may ultimately cover  
23 substantially the same subject matter." *Id.*

24 The fact that a preferred embodiment (or even all of the preferred embodiments) described in  
25 the specification possesses a feature corresponding to the requested limitation is not sufficient to  
26 rebut the presumption of claim differentiation. *See Acumed LLC v. Stryker Corp.*, 483 F.3d 800,  
27 805-806 (Fed. Cir. 2007) (holding that claim term should not be construed narrowly based on a  
28 feature in a preferred embodiment where such a construction would give a dependent claim the same

1 meaning as the independent claim). Similarly, language in the specification describing the “object”  
2 or purpose of an invention has been held insufficient to overcome the presumption of claim  
3 differentiation. *E-Pass Technologies, Inc. v. 3Com Corp.*, 343 F.3d 1364, 1369-1370 (Fed. Cir.  
4 2003) (“An invention may possess a number of advantages or purposes, and there is no requirement  
5 that every claim directed to that invention be limited to encompass all of them”); *see also*  
6 *Howmedica Osteonics Corp. v. Wright Medical Technology, Inc.*, 540 F.3d 1337, 1345 (Fed. Cir.  
7 2008) (rejecting limitation that was offered on the basis of purposes of the invention in the  
8 specification because “[t]he court’s task is not to limit claim language to exclude particular devices  
9 because they do not serve a perceived ‘purpose’ of the invention”).

10 On the other hand, the presumption that arises under the doctrine of claim differentiation may  
11 be rebutted where the specification includes a description of “the present invention” and this  
12 language, when read in the context of the claims, specification and prosecution history, describes the  
13 invention as a whole. *Netcraft Corp. v. eBay, Inc.*, 549 F.3d 1394, 1398 (Fed. Cir. 2008) (holding  
14 that language describing “present invention,” when read in light of the specification and prosecution  
15 history, described entire invention and therefore had to be reflected in claim constructions). For  
16 example, in *Verizon Services Corp. v. Vonage Holdings Corp.*, the Federal Circuit addressed the  
17 meaning of the claim term “localized wireless gateway system.” 503 F.3d 1295, 1308 (Fed. Cir.  
18 2007). The court noted that “[i]n the course of describing the ‘present invention,’ the specification  
19 then states that ‘[t]he gateway compresses and decompresses voice frequency communication  
20 signals and sends and receives the compressed signals in packet form via the network.’” *Id.* (citation  
21 omitted). The court concluded that this description limited the scope of the invention as a whole and  
22 on that basis concluded that the term “localized wireless gateway system” “must be limited to one  
23 performing compression and packetization functions at the gateway.” *Id.*

24 The Federal Circuit’s decision in *Yoon Ja Kim v. ConAgra Foods, Inc.*, 465 F.3d 1312 (Fed.  
25 Cir. 2006), cited by DrugLogic, also illustrates these rules. In that case, the court construed the term  
26 “potassium bromate replacer.” *Id.* at 1318. It concluded that the construction should include a  
27 limitation requiring that the potassium bromate replacer must be “functional” on the basis of the  
28 following language in the specification: “the present invention is particularly useful [in] that it

1 provides natural ascorbic acid as the only oxidizing agent in dough that is effective and functional  
 2 throughout the entire manufacturing process.” *Id.* (quoting patent). The Federal Circuit held that  
 3 “[w]hen the claim limitation is read against this backdrop, it is clear that the potassium bromate  
 4 replacer must be functional.” *Id.*

5 On the other hand, the Federal Circuit rejected a more limited construction of “potassium  
 6 bromate replacer” as “a slow acting oxidant that is functional throughout the entire manufacturing  
 7 process.” *Id.* at 1319. The court stated that “[t]he mere fact that one object of the invention is to  
 8 produce a slow acting oxidant which is functional throughout the entire manufacturing process does  
 9 not mean that this particular feature was adopted as a limitation in each claim of the patent.” *Id.* It  
 10 explained further:

11 The specification does not require that the potassium bromate replacer must necessarily be a  
 12 slow acting oxidant, only that particular potassium bromate replacers perform that function. .  
 13 . Thus the fact that the patent here discloses the advantages of a slow acting oxidant does not  
 14 mean that all the claims are directed to such an oxidant. *See E-Pass Tech., Inc. v. 3Com*  
*Corp.*, 343 F.3d 1364, 1368-69 (Fed. Cir. 2003). Indeed, Kim chose to claim a “slow acting”  
 15 oxidant in dependent claim 7, while her independent claims were directed to a more general  
 16 potassium bromate replacer. The doctrine of claim differentiation suggests that the  
 17 independent claims here should not include explicit limitations of a dependent claim.

18 *Id.*

19 Here, the language in the specification does not merely describe an advantage of the  
 20 invention or a feature of a preferred embodiment. Rather, it categorically states that “[t]he analysis  
 21 provided by the system of the present invention finds ‘signals’ such as anomalies in a random  
 22 population, a change against a known background, or a coherent target in a noise background.” ‘091  
 23 patent, col. 20, ll. 54-57. Because nothing in the specification or prosecution history supports a  
 24 contrary conclusion, and based on the clear language in the specification, the Court concludes that  
 25 this language describes the entire invention and therefore, that Oracle’s proposed construction is  
 correct.<sup>8</sup> Therefore, the Court construes the term “permitting the at least one remote user to analyze

---

26 <sup>8</sup>DrugLogic’s reliance on this Court’s decision in *Augme Techs., Inc. v. Yahoo!, Inc.* is  
 27 misplaced. *See* 2011 U.S. Dist. LEXIS 109886 at \*48-51 (N.D. Cal. Sept. 27, 2011). In *Augme*, the  
 28 Court explained that while the specification contained “present invention” language describing the  
 function of the invention in terms of “media appliance metaphors,” it also contained an express  
 disclaimer stating that the invention was not limited to media appliance metaphors. As noted above,

1 safety issues” as follows: “permitting the at least one remote user to run a statistical analysis that  
2 finds ‘signals’ such as anomalies in a random population, changes against a known background, or  
3 coherent targets in a noise background.”

b. **“permitting at least one remote user to access such data through the World Wide Web”**

DrugLogic's Proposed Construction	Oracle's Proposed Construction
<p>“permitting a user at one computer to access the information reflecting occurrences of adverse events on a different computer or server through a collection of web pages containing hyperlinks to other web pages and transmitted using TCP/IP or HTTP protocols”</p>	<p>“permitting a user on one network to access the previously stored information residing on a different network through a series of Internet servers using a standard Web browser, without using special software or downloads”</p>

### i. Parties' Positions

DrugLogic identifies two disputes relating to this claim term: “1) whether a user must access data on a different computer or on an entirely distinct network to be considered a ‘remote user,’ and 2) whether ‘through the World Wide Web’ means accessing data through a ‘standard Web browser, without using special software or download’ or simply through ‘a collection of web pages containing hyperlinks to other web pages and transmitted using TCP/IP or HTTP protocols.’” DrugLogic’s Opening Brief (‘091 Patent) at 8.

17       Regarding the meaning of “remote user,” DrugLogic argues that the ordinary meaning of this  
18 term is “an individual ‘who works on a computer from a remote location.’” *Id.* (quoting Tech Terms  
19 Computer Dictionary, [www.techterms.com](http://www.techterms.com) (2012)) & Ex. 2. This definition finds further support in  
20 the specification, DrugLogic contends. *Id.* at 8-9. In particular, the specification provides that “[a]  
21 web browser makes a connection via the WWW to other computers known as web servers, and  
22 receives information from the web servers that is displayed on the user’s workstation.” *Id.* at 9  
23 (quoting ‘091 patent, col. 10, ll. 39-42). DrugLogic also points to the following passage in the  
24 specification:

25 The web-based aspect of the assessment of adverse effects of one or more drugs of the present invention also permits multiple simultaneous users. This feature of the present

28 | the specification of the '091 patent contains no such language or disclaimer.

1 invention is important in assessors who, although working for the same organization are in  
2 different locations.

3 *Id.* (quoting ‘091 patent, col. 13, ll. 10-15).

4 DrugLogic further contends that Oracle’s proposed construction is incorrect to the extent that  
5 it requires that a remote user utilize a different network because it contradicts the specification.  
6 DrugLogic Opening Brief (‘091 Patent) at 9. DrugLogic quotes the following passages it contends  
7 shows that users of the invention may communicate over a single network:

8 Networks for personal computers were developed to allow individual users to communicate  
9 with each other. In this manner, a large number of people within a company could  
communicate simultaneously over *a network* with a software application running on a single  
computer system.

10 *Id.* (quoting ‘091 patent, col. 10, ll. 24-29) (emphasis in DrugLogic’s brief).

11 The Web permits web-based applications. Such web-based applications use TCP/IP and  
12 HTTP protocols to transport information from a *central network application server* to Web  
13 clients and back.

14 *Id.* (quoting ‘091 patent, col. 5, l. 66-col. 6, l. 2) (emphasis in DrugLogic’s brief) .

15 Although numerous system architectures may be used to implement the inventive technique,  
16 one particularly advantageous architecture is implemented, for example, in a corporate  
17 enterprise (such as an intranet), wherein a plurality of client machines (desktops) interface  
with a support center located at a server node through a network.

18 *Id.* (quoting ‘091 patent, col. 11, ll. 45-51).

19 With respect to the meaning of “through the World Wide Web,” DrugLogic argues that its  
20 proposed construction – which does not require that the invention work with a standard web browser  
21 and without the use of special software – is supported by the specification. *Id.* at 9. DrugLogic  
22 points to the following passages in the specification:

23 The World Wide Web is a system of Internet servers that support specially formatted  
24 documents. The documents are formatted in a language called HTML...that supports links to  
other documents.... This means a user can jump from one document to another simply by  
clicking on hot spots.

25  
26 *Id.* (quoting ‘091 patent, col. 5, l. 56 - col. 6, l. 5).

27 T]he Internet grew out of the modern proliferation of computers and networks, and has  
28 evolved into a sophisticated worldwide network of computer systems linked together by web  
pages that collectively make up the “world wide web[.]”

1 *Id.* at 10 ('091 patent, col. 10, ll. 32-36).

2 The Web permits web-based applications. Such web-based applications use TCP/IP and  
3 HTTP protocols to transport information from a central network application server to Web  
clients and back.

4 *Id.* (quoting '091 patent, col. 5, l. 66 - col. 6, l. 2).

5 DrugLogic also cites extrinsic evidence in support of its proposed construction, namely, the  
6 following description of the World Wide Web on Webopedia, which describes the World Wide Web  
7 as follows:

8 The [World Wide] Web uses the HTTP protocol, only one of the languages spoken over the  
9 Internet, to transmit data. Web services, which use HTTP to allow applications to  
10 communicate in order to exchange business logic, use the Web to share information. The Web  
also utilizes browsers, such as Internet Explorer or Firefox, to access Web documents called  
Web pages that are linked to each other via hyperlinks.

11 *Id.* & Ex. 3 (Webopedia, [www.webopedia.com](http://www.webopedia.com), (2012)). DrugLogic also quotes the Federal Circuit,  
12 which has stated:

13 The World Wide Web, a collection of files, or "web pages," containing text, graphics, audio,  
14 and video, as well as "hyperlinks" to other web pages, has become a central part of the  
15 Internet. Consumers typically access the web using client software applications known as  
16 web browsers that run on their personal computers.

17 *Id.* (quoting *Resonate, Inc. v. Alteon Websystems, Inc.*, 338 F.3d 1360, 1361 (Fed. Cir. 2003)).

18 DrugLogic concedes that the specification contains language that tracks Oracle's proposed  
19 construction, stating that "the web-based analysis of adverse drug effects of the present invention  
20 further permits the application to be run from a server and accessed by standard browsers, thus  
21 obviating the need for special software or downloads." *Id.* (quoting '091 patent, col. 6, ll. 55-59).  
22 However, DrugLogic contends that this language does not require that standard Web browsers be  
23 used or that special software or downloads be excluded because it merely sets forth an advantage of  
24 the invention. *Id.* (citing *Phillips v. AWH Corp.*, 415 F.3d 1303, 1327 (Fed. Cir. 2005)). Further,  
25 because this language is permissive rather than definitional, DrugLogic asserts, it does not impose  
26 any limitation on the scope of the claim. *Id.* at 11 (citing *Sunrace Roots Enter. Co. v. SRAM Corp.*,  
27 336 F.3d 1298, 1304-05 (Fed. Cir. 2003); *Nomadix, Inc. v. Hewlett-Packard*, 2011 U.S. Dist. LEXIS  
122823 at \*12 (C.D. Cal. Oct. 24, 2011)).

1       With respect to language in the specification discussing use of a web browser to access the  
2 World Wide Web, *see, e.g.*, ‘091 patent, col. 5, ll. 64-64 & col. 10, ll. 36-39, this language does not  
3 trump the clear meaning of the claim term, DrugLogic asserts. *Id.* (citing *Comark Communs. Inc. v.*  
4 *Harris Corp.*, 156 F.3d 1182, 1187 (Fed. Cir. 1998)). Moreover, DrugLogic asserts, the  
5 specification discloses alternatives, stating “[t]he interface for the system could be the familiar  
6 unmodified Web browser, a Web browser customized with special features, or a unique Web  
7 application.” *Id.* (quoting ‘091 patent, col. 6, ll. 2-4).

8       Finally, DrugLogic argues that “Oracle’s own marketing materials and user’s manuals belie  
9 their proposed construction” to the extent they recognize the Web is a “network of servers that  
10 contain programs and files [in which] . . . many of the files contain hypertext links to other  
11 documents available through the network.” *Id.* & Ex. 4 (excerpt from Oracle’s user’s manual).

12      Oracle responds that there is no dispute as to the meaning of the term “remote user” and that  
13 the only dispute between the parties is “whether accessing data ‘through the World Wide Web’  
14 includes a user accessing data located within that user’s private network.” Oracle Responsive Brief  
15 at 19. According to Oracle, the term “through the World Wide Web,” by its plain language,  
16 “requires use of the world-wide system of Internet servers that make up the ‘World Wide Web.’”  
17 *Id.* (citing ‘091 patent, col. 5, ll. 56-60). DrugLogic’s position, Oracle asserts, “flies in the face of  
18 the claimed functionality of the ‘091 patent, and so must be rejected.” *Id.*

19      Oracle argues that the ‘091 specification “touts the use of the World Wide Web . . . as a  
20 prime innovation” of the ‘091 patent, citing the following passages of the ‘091 specification:  
21 “Access to the present invention is provided by means of the Web.” (col. 12, ll. 38-39); “[N]one of  
22 [the prior art] references provides a web-based system and method for analyzing the risks of adverse  
23 effects resulting from the use of a particular drug . . .” (col. 4, ll. 24-28); “The system of the present  
24 invention is a web-based system . . .” (col. 4, ll. 41-42). *Id.* at 20. Oracle also cites the  
25 specification’s description of the Web as a “sophisticated worldwide network of computer systems  
26 linked together by web pages.” *Id.* (quoting ‘091 patent, col. 10, ll. 31-45). Oracle further points to  
27 statements that “[a] user at an individual PC (i.e., workstation) that wishes to access the WWW  
28 typically does so using a software application known as a web-browser” and that “[a] web browser

1 makes a connection via the WWW to other computers known as web servers, and receives  
2 information that is displayed in the user's workstation." *Id.* (quoting '091 patent, col 10, ll. 36-39 &  
3 ll. 38-42).

4 Further, Oracle contends, the specification offers detailed reasons why the use of the Web is  
5 important to the effective analysis of the risks of adverse effects resulting from a drug. *Id.* (citing  
6 '091 patent, col. 6, ll. 42-46 ("the web-based analysis of adverse drug effects of the present  
7 invention permits multiple users to concurrently assess the hypotheses regarding the possible  
8 existence and causation of the adverse drug effects"); col. 6, ll. 47-51 ("[t]he web-based analysis of  
9 adverse drug effects of the present invention also permits users to assess hypotheses regarding the  
10 possible existence and causation of the adverse drug effects on a continuous, real-time basis, 24  
11 hours a day, 7 days a week"); col. 6, ll. 52-54 ("[t]he web-based analysis of adverse drug effects of  
12 the present invention further permits users to access the application world-wide, without any  
13 geographic limitation"); col. 6, ll. 60-62 ("[t]he above-described geographic and coherent/consistent  
14 advantages permit greater cooperation among researchers, even if affiliated with different  
15 organizations"); col. 6, ll. 55-59 ("the web-based analysis of adverse drug effects of the present  
16 invention further permits the application to be run from a server and accessed by standard browsers,  
17 thus obviating the need for special software or downloads"). Oracle argues that these clauses *are*  
18 definitional, notwithstanding DrugLogic's assertions to the contrary. *Id.* 21. Thus, the statement  
19 that "the present invention" "obviate[s] the need for special software or downloads" "means that any  
20 sort of 'web-based analysis' that does require 'special software or downloads' is not the web-based  
21 analysis of the '091 patent." *Id.* (citing *SunRace Roots Enter. Co., Ltd. v. SRAM Corp.*, 336 F.3d  
22 1298, 1304 (Fed. Cir. 2003)).

23 Oracle further contends that its proposed construction is consistent with technical  
24 dictionaries at the time of the filing of the '091 patent. *Id.* at 21. Oracle cites the 2001 edition of  
25 Newton's Telecom Dictionary, which defines the World Wide Web as "the universe of accessible  
26 information available on many computers spread through the world and attached to that gigantic  
27 computer network called the Internet." *Id.* (citing Von Der Ahe Decl., Ex. O).

28

1 Oracle argues that DrugLogic's reliance on *Phillips* is misplaced because in that case, the  
2 court refused to import a limitation from the specification because the limitation was already  
3 included in the patent's other claims. *Id.* (citing 415 F.3ds at 1327). That is not the situation here,  
4 Oracle contends, because only claims 1 and 8 discuss the World Wide Web. *Id.* Oracle also rejects  
5 DrugLogic's reliance on *Nomadix*. *Id.* According to Oracle, in that case the court refused to import  
6 a limitation from a preferred embodiment. *Id.* (citing 2011 U.S. Dist. LEXIS 122823, at \* 12 (C.D.  
7 Cal. Oct. 24, 2011)). Here, in contrast, "Oracle is not drawing its proposed claim language from a  
8 preferred embodiment but directly from the '091 patent's description of the 'present invention.'" *Id.*  
9 (*citing Alloc, Inc. v. Int'l Trade Comm'n*, 342 F.3d 1361, 1368-1370 (Fed. Cir. 2003)).

10 In its response, DrugLogic argues that the exclusion of private networks under Oracle's  
11 proposed construction contradicts the specification, which describes a private network as a preferred  
12 embodiment. DrugLogic Reply Brief ('091 patent) at 3-4 (citing '091 patent, col. 11, ll. 45-51).  
13 Such a construction is ordinarily incorrect, DrugLogic contends. *Id.* at 4 (*citing Verizon Servs.*  
14 *Corp. v. Vonage Holdings, Corp.*, 503 F.3d 1295, 1305 (Fed. Cir. 2007)). DrugLogic challenges  
15 Oracle's reliance on statements in the specification providing "that the web-based analysis aspect of  
16 'the present invention' permits certain advantages." *Id.* (citing Oracle Responsive Brief ('091  
17 patent) at 24; '091 patent, col. 6, ll. 42-63). According to DrugLogic, Oracle provides no support for  
18 its contention that private networks cannot offer these advantages and in any event, the word  
19 "permit" in the specification is not a term of exclusion. *Id.* (*citing SunRace Roots Enterprises Co.,*  
20 *Ltd. v. SRAM Corp.*, 336 F.3d 1298, 1304 (Fed. Cir. 2003)). DrugLogic argues that the statements  
21 cited by Oracle merely describe the advantages of the invention and therefore are not limiting. *Id.*  
22 (*citing Kim v. ConAgra Foods, Inc.*, 465 F.3d 1312, 1319 (Fed. Cir. 2006); *Brookhill-Wilk 1, LLC v.*  
23 *Intuitive Surgical, Inc.*, 334 F.3d 1294, 1301 (Fed. Cir. 2003); *Flexhead Indus. Inc. v. Easyflex, Inc.*,  
24 2008 U.S. Dist. LEXIS 91848 \* 9-10 (D. Mass. Nov. 3, 2008)).

25 Finally, as to Oracle's position that the claims do not cover use of special software and  
26 downloads, DrugLogic argues again that this is merely one *advantage* of the claims; the fact that it is  
27 not required, DrugLogic asserts, is illustrated by the statement in the specification describing  
28 implementation of the invention with a "Web browser with customized features" or a "unique web

1 application.” *Id.* According to DrugLogic, customized features or unique web applications are  
2 “often installed using special software or downloads.” *Id.* at 5.

3 **ii. Analysis**

4 The primary dispute with respect to this claim term is whether the words “through the World  
5 Wide Web” permit a construction that includes a user accessing data that is located solely within a  
6 private network, or intranet. The parties also dispute whether the term should be construed to  
7 include a limitation requiring that the user must be able to access previously stored information  
8 “using a standard Web browser, without using special software or downloads.” As to the first  
9 question, the Court concludes that this claim term requires use of one or more Internet servers to  
10 access data. The ability to practice the invention using a standard web browser, however, is simply  
11 an advantage of the invention that is not properly included in the Court’s construction of this claim  
12 term.

13 The Court starts with the words of the claim, which expressly state that the claimed invention  
14 permits “access . . . through the World Wide Web.” ‘091 Patent, claim 1. Any question as to the  
15 meaning of these words is dispelled by the specification, which defines the World Wide Web as “a  
16 system of Internet servers that support specially formatted documents.” ‘091 patent, col. 5, ll. 56-57.  
17 Further, the specification repeatedly describes the invention as being “web-based,” pointing to this  
18 aspect of the invention as a key feature distinguishing it from the prior art. *See* ‘091 patent, col. 12,  
19 ll. 38-39 (“Access to the present invention is provided by means of the Web.”); col. 4, ll. 24-28  
20 (“[N]one of [the prior art] references provides a web-based system and method for analyzing the  
21 risks of adverse effects resulting from the use of a particular drug . . .”); col. 4, ll. 41-42 (“The  
22 system of the present invention is a web-based system . . .”). In touting this advantage of the  
23 invention over the prior art, the specification makes clear that the words “through the World Wide  
24 Web” require that access must be through one or more Internet servers and that the invention does  
25 not include embodiments that utilize only a private intranet. *See Tronzo v. Biomet*, 156 F.3d 1154,  
26 1159 (Fed. Cir. 1998).

27 The language in the specification cited by DrugLogic referring to the use of the invention  
28 within a single company or organization, *see e.g.*, ‘091 patent, col. 10, ll. 24-29, col. 11, ll. 45-51,

1 col. 13, ll. 10-15, does not persuade the Court that “access . . .through the World Wide Web”  
2 includes an embodiment using only an intranet where there is no access to an Internet server.  
3 Rather, the specification explains that an intranet can be used *together with* a Web server. *See* ‘091  
4 patent, col. 11, l. 56 - col. 12, l. 12. Nothing in the specification suggests that use of an intranet  
5 alone satisfies this claim term.

6 Next, the Court addresses Oracle’s proposed limitation, “using a standard Web browser,  
7 without using special software.” This language tracks the disclosure in the specification stating that  
8 “the web-based analysis of adverse drug effects of the present invention further permits the  
9 application to be run from a server and accessed by standard browsers, thus obviating the need for  
10 special software or downloads.” ‘091 patent, col. 6, ll. 55-59. The Court looks to the cases cited by  
11 the parties for guidance on the question of whether the ability to use a standard Web browser  
12 without special software is a limitation or whether it merely describes an advantage that is associated  
13 with a preferred embodiment of the invention.

14 In *SunRace Roots*, cited by both parties, the Federal Circuit addressed whether the claim term  
15 “shift actuator” should be construed more restrictively than its ordinary meaning. 336 F.3d at 1304.  
16 The district court had limited the meaning of the claim term to a device containing the cam structure  
17 of the preferred embodiment, relying on language in the specification 1) describing “one of the  
18 objects of the invention;” 2) describing an “important part of the invention;” 3) stating that “[e]ach  
19 handgrip shift actuator contains a generally cylindrical cam member having a generally helical  
20 operating face configured with a plurality of spaced detents or valleys with a cam peak or lobe  
21 between each pair of adjacent detents;” and 4) stating that “[a] rotary cam member 74 having a  
22 generally helical operating face is the heart of the rear handgrip shift actuator.” *Id.* The Federal  
23 Circuit concluded that these statements did not “sufficiently evidence an intention to depart from the  
24 ordinary meaning of “shift actuator.”” *Id.*

25 With respect to the first two passages, the Federal Circuit explained, these statements  
26 “simply detail[ed] some of the goals of the invention that are achieved by some of the apparatus  
27 claims.” *Id.* These did not limit the meaning of the claim term, however, because the specification  
28

1 also recited other goals that did not address the use of cams. *Id.* The third and fourth statements  
2 were “more problematic” but the Federal Circuit found that they “still [did] not define the term shift  
3 actuator” and did not constitute expressions of “clear exclusion” but instead was “more properly  
4 characterized as descriptive of the preferred embodiments.” *Id.* While acknowledging that a claim  
5 term can be given a narrow construction based on a preferred embodiment where the patent has  
6 described the preferred embodiment as the invention itself, the court found that that approach did not  
7 apply, citing the fact that an original claim recited a shift actuator generally whereas another called  
8 for a *handgrip* shift actuator. *Id.* The court concluded that patentees had “contemplated a broad  
9 class of shift actuators containing a subcategory of handgrip shift actuators, which in turn contained a  
10 subcategory of handgrip shift actuators employing a cam mechanism.” *Id.* at 1304-1305.

11 In *Nomadix*, cited by DrugLogic, the court addressed whether the term “management  
12 system” should be limited to a system that was “connected to the gateway device by a direct link.”  
13 2011 U.S. Dist. LEXIS, at \* 11-12 (C.D. Cal. 2011). The party seeking the limitation quoted the  
14 following statements in the specification: the “network gateway devices communicat[e] with  
15 management systems;” that “according to one aspect of the invention, the gateway device is in direct  
16 communication with the management system;” and that “[t]ypically the gateway device [] is  
17 connected . . . to the management system.” *Id.* at \*12. The court concluded that “[n]one of [this]  
18 language require[d] that the management system must be physically connected to the gateway  
19 device.” *Id.* Instead, the court concluded that the term needed no construction. *Id.*

20 In *Alloc, Inc. v. Valinge Aluminium, AB*, cited by Oracle, the Federal Circuit held that a  
21 patent was directed to flooring systems and methods of joining those flooring systems with play  
22 between the locking groove and the locking element, even though none of the claim terms included  
23 the word “play.” 342 F.3d at 1370. In reaching this conclusion, the court relied on the following  
24 description of the invention, under the heading of “Technical Problems and Objects of the  
25 Invention:”

26 provid[ing] a system for making a joint along adjacent joint edges of two building panels,  
27 especially floor panels . . . said system being characterized in that . . . the panels, when joined  
28 together, can occupy a relative position in said second direction where a play exists between

1 the locking groove and a locking surface on the locking element that is facing the joint edges  
2 and is operative in said second mechanical connection.

3 *Id.* at 1368-1369. The court went on to point to language stating that the “objects of the invention  
4 are achieved by means of a panel-joining system having the features recited in the appended claims.”  
5 *Id.* at 1369. The court also relied on language in the specification describing the various advantages  
6 a system with play permitted, such as “displacement” and “disassembly and reassembly of a floor  
7 previously laid without causing damage to the panels.” *Id.* Finally, the court pointed to language in  
8 the specification criticizing prior art floor systems that did not have play. *Id.* at 1369-1370.

9 The Court concludes that the language in the ‘091 patent referring to the ability to use the  
10 invention without special software, like the language in *SunRace Roots* and *Nomadix*, is not  
11 definitional language that constitutes an expression of clear exclusion. Rather, it describes a  
12 preferred embodiment.

13 The Court construes the term “permitting at least one remote user to access such data through  
14 the World Wide Web” as follows: “permitting a user at one computer to access information reflecting  
15 occurrences of adverse events on a different computer or server, through one or more Internet  
16 servers.”

1                   **3. Disputed Claim Terms From Dependent Claims 4-6 and 11-13**

2                   a.       **“a comparator to measure the reactions to the at least one**  
 3                   **[drug/substance]<sup>9</sup> of interest against a user-defined backdrop”**  
 4                   **(Claims 4 and 11) and “comparator” (Claims 6 and 13)**

5                   DrugLogic’s Proposed Construction	6                   Oracle’s Proposed Construction
6                   “an application that compares the reactions to a 7                   particular drug of two user-defined data sets”	7                   “an analysis tool that compares the potential 8                   adverse effects of a drug in the premarket 9                   environment to the actual adverse effects of 10                  that drug in the post-market environment”

8                   **i. The Parties’ Positions**

9                   DrugLogic contends that its proposed construction is consistent with the language of claims  
 10                  4 and 11. DrugLogic Opening Brief (‘091 patent) at 20. Claims 4 and 11 provide, in part, as  
 11                  follows:

12                  The computer-implemented method for assessing and analyzing the risks of adverse effects  
 13                  resulting from the use of at least one [drug/substance] of interest . . . wherein the at least one  
 14                  data mining engine is a comparator to measure the reactions to the at least one drug of  
 15                  interest against a user-defined backdrop.

16                  ‘091 patent, claims 4 & 11. According to DrugLogic, this language “defines a comparator as an  
 17                  application that compares the reactions to a particular drug of two user-defined data-sets.”

18                  DrugLogic Opening Brief (‘091 patent) at 20. Further, it contends, the specification confirms this  
 19                  construction, stating that “[t]he comparator can compare any two sets of cases for any two  
 20                  dimensions.” *Id* (quoting ‘091 patent, col. 24, ll. 30-31). DrugLogic acknowledges that the  
 21                  specification describes a comparator that allows a user to compare reactions reported in pre-market  
 22                  data to reactions reported in post-market data, but argues that this is a preferred embodiment. *Id.* at  
 23                  20-21 (citing ‘091 patent, col. 24, ll. 1-22 (describing comparator in the “preferred offering” as  
 24                  comparing pre- and post-market data); col. 15, ll. 29-35 (stating that “an additional preferred aspect  
 25                  of this home page is the comparator . . . [which] compares potential and adverse effects of drugs in  
 26                  the pre- and post- market environments”)).

27                  

---

 28                  <sup>9</sup>Claim 4 uses “drug” throughout while claim 11 uses “substance” throughout.

1 Oracle argues that this claim term is limited to a comparator that compares pre-market  
2 reactions to post-market reactions, asserting that every reference to the comparator is definitional,  
3 describing the “comparator engine of the present invention” and therefore is not simply describing  
4 preferred embodiments. Oracle Responsive Brief (‘091 patent) at 22-23. In particular, Oracle points  
5 to the following two passages of the specification:

6 The comparator engine of the present invention is a differencing engine that is applied to  
7 measuring one drug’s reactions, both pre-and post- market.

8 *Id.* (quoting citing ‘091 patent, col. 24, ll. 23-25).

9 The comparator compares potential and adverse effects of drugs in the pre- and post-market  
10 environments.

11 *Id.* at 22-23 (quoting ‘091 patent, , col. 15, ll. 33-35).

12 Oracle concedes that a comparator that allows for a comparison of pre- and post- market  
13 reactions is described in the patent as part of the preferred embodiment, but contends that this is also  
14 an essential feature of the “present invention.” *Id.* n. 8 (citing DrugLogic Opening Brief (‘091  
15 Patent) at 20 (quoting ‘091 patent, col. 24, ll. 1-22, col. 15, ll. 29-35)). Oracle also points to Figures  
16 2 in support of its position, showing the three data mining engines of the ‘091 patent as the  
17 “Proportional” engine, the “Correlator” engine and the “pre-post” engine. *Id.* at 23. Based on a  
18 passage in the specification referring to the three data-mining engines of the ‘091 patent as the  
19 “Proportional” Engine, the “Comparator” engine and the “Correlator” engine, Oracle contends that  
20 the term “comparator” in the ‘091 patent is used interchangeably with “pre-post market” engine,  
21 showing that this is an essential element of the comparator. *Id.* Oracle also points to Figure 20,  
22 which is described as “an illustration of a comparator screen of the present invention.” ‘091 patent,  
23 col. 8, ll. 32-33. The screen in that figure includes “Pre-Post Market” in the heading.

24 In its reply, DrugLogic reiterates its position that the language of the specification makes  
25 clear that the comparator allows the comparison of pre- and post market reactions in preferred  
26 embodiments but that the comparator can be used to compare other user-defined data sets as well.  
27 DrugLogic’s Reply Brief (‘091 patent) at 14-15.

28

## ii. Analysis

2 The Court starts its analysis with the plain language of the claims. Claims 4 and 11 require  
3 only that the comparator allow for the comparison of reactions as to two data sets or criteria. They  
4 do not require that the comparisons must be *between* pre-market data and post-market data.  
5 Admittedly, the specification states that the “comparator compares potential and actual adverse  
6 effects of drugs in the pre- and post- market environment.” ‘091 patent, col. 15, 33-35. As a matter  
7 of basic grammar, however, this does not require that pre-market data must be compared to post-  
8 market data. Rather, it simply means that the comparison can be conducted as to both pre- and post-  
9 market data. Similarly, the passage stating that “[t]he comparator engine of the present invention is  
10 a differencing engine that is applied to measuring one drug’s reactions, both pre- and post-market,”  
11 ‘091 patent, col. 24, ll. 23-25, does not state that pre- market data must be compared to post-market  
12 data. Further, the Court concludes that Figures 2 and 20, which appear to depict a comparator that  
13 compares pre-market data to post-market data, are preferred embodiments and do not support  
14 importing this limitation into the Court’s construction of this claim term. Accordingly, the Court  
15 adopts DrugLogic’s proposed construction, construing the terms “a comparator to measure the  
16 reactions to the at least one [drug/substance] of interest against a user-defined backdrop” and  
17 “comparator” as “an application that compares the reactions to a particular drug of two user-defined  
18 data sets.”

Term	DrugLogic's Proposed Construction	Oracle's Proposed Construction
“a correlator to look for correlated signal characteristics among drug, reaction, and demographic information”	“an analysis tool that measures the degree of association among pairs of certain drug, reaction, and demographic values”	<p><b>Initial:</b> “an analysis tool that uses an algorithm to measure the degree of correlation between drug, reaction, and demographic information concurrently”</p> <p><b>Modified:</b> “an analysis tool that concurrently measures the degree of correlation among multiple pairs of drug, reaction, and demographic information”</p>
“correlator”	“an analysis tool that measures the degree of association among pairs of values”	Same as above

### i. Parties' Positions

16 DrugLogic contends that its proposed construction of these claim terms is true to the claim  
17 language. DrugLogic Opening Brief ('091 patent) at 21. In particular, claims 5 and 12 provide for a  
18 "correlator to look for correlated signal characteristics among drug, reaction and demographic  
19 information." *Id.* (quoting '091 patent, claims 5 and 12). Oracle's proposed construction is not  
20 helpful, DrugLogic asserts, to the extent it "essentially provides that a correlator measures  
21 correlation." *Id.* Instead, DrugLogic points to the specification, which it contends provides a "better  
22 definition," stating: "[t]he correlator looks for the association of characteristics in literally millions  
23 of pieces of drug/ reaction/ demographic information concurrently." *Id.* at 21 (quoting '091 patent,  
24 col. 20, ll. 65-67). According to DrugLogic, Oracle's proposed construction is inconsistent with this  
25 language in the specification, with the word "concurrently" implying that drug, reaction and  
26 demographic information all must be measured for correlation at the same time. *Id.* DrugLogic  
27 argues that in fact, only two data elements need be measured together, quoting the following passage

1 in the specification:

2 Too often in risk assessment, important correlations are hidden by surrounding background  
3 ‘noise’ that obscures connections among data elements. Using a multidimensional vector  
4 analysis, the correlator measures the degree of association among pairs of values (for  
example, a drug and a reaction, an age and an outcome, etc.).

5 *Id.* at 22 (quoting ‘091 patent, col. 21, ll. 1-7).

6 In response, Oracle argues that its proposed construction is correct because “[a] ‘correlator’  
7 necessarily measures the degree of ‘correlation’ between the variables,” implicitly rejecting  
8 DrugLogic’s use of the word “association” in its proposed construction. Oracle’s Responsive Brief  
9 (‘091 patent) at 24. More importantly, Oracle asserts, DrugLogic’s proposed construction does not  
10 reflect the requirement that the correlator use “a multidimensional vector analysis.” *Id.* (quoting  
11 ‘091 patent, col. 21, ll. 3-6 (“Using a multidimensional vector analysis, the correlator measures the  
12 degree of association among pairs of values (for example, a drug and a reaction, an age and an  
13 outcome, etc.”). That requirement is captured in Oracle’s proposed construction, it contends, by the  
14 word “concurrently,” which is consistent with the language in the specification describing the  
15 correlator as “look[ing] for the association of characteristics in literally millions of pieces of  
16 drug/reaction/demographic information concurrently.” *Id.* (quoting ‘091 patent, col. 20, ll. 65-67).  
17 Oracle also points to Figure 13, which demonstrates that the correlator “simultaneously runs across  
18 multiple dimensions (including sex, target drug, reaction and outcome), in order to achieve its  
19 results.” *Id.* at 24-25. Oracle concedes that the correlator compares pairs of values, however, and  
20 therefore modifies its proposed construction to the following: “an analysis tool that concurrently  
21 measures the degree of correlation among multiple pairs of drug, reaction, and demographic  
22 information.” *Id.* at 25.

23 In its reply brief, DrugLogic rejects Oracle’s modified proposed construction. DrugLogic’s  
24 Reply Brief (‘091 patent) at 15-16. First, it reiterates its position that Oracle’s proposed construction  
25 will not be helpful to the jury to the extent it defines a correlator as something that measures  
26 correlations. *Id.* at 15. Second, it contends that Oracle’s modified construction does not remedy the  
27 problem DrugLogic identified in its opening brief, namely, suggesting that all three values – drug,  
28

1 reaction and demographic information – must be measured for correlation concurrently.<sup>10</sup> *Id.*

2 **ii. Analysis**

3 The disputes relating to this claim term do not appear to be based on any fundamental  
4 disagreements about the function of the correlator in the '091 patent or how that function is  
5 performed. Oracle agrees that the correlator measures correlations between *pairs* of values, while  
6 DrugLogic does not dispute that the means of performing this operation is by multidimensional  
7 vector analysis. Rather, the parties' disagreements turn on whose proposed construction best  
8 conveys to the jury what these terms mean. The Court adopts a modified construction that adopts  
9 some elements of the constructions proposed by the parties.

10 First, as to whether the correlator should be construed as something that measures the degree  
11 of "association" as opposed to the degree of "correlation" between pairs of values, the Court finds  
12 no difference in meaning between the two. Indeed, the patentee appears to have used them  
13 interchangeably. *See* '091 patent, col. 21, ll. 4-5. Therefore, the Court adopts in its construction the  
14 word "association" rather than "correlation" as it may be helpful for the jury to be offered a  
15 synonym for "correlation."

16 Second, the Court agrees with Oracle that DrugLogic's proposed construction does not  
17 convey the multidimensional aspect of the analysis conducted by the correlator. On the other hand,  
18 Oracle's proposed construction is, arguably, somewhat awkward and possibly confusing. Therefore,  
19 the Court construes "a correlator to look for correlated signal characteristics among drug, reaction,  
20 and demographic information" and "correlator" as follows: "an analysis tool that concurrently  
21 searches drug, reaction and demographic information to measure the degree of association among  
22 pairs of certain drug, reaction, and demographic values."

23

24

25

26

---

27 <sup>10</sup>The Court notes that neither side addresses the stand-alone term "correlator," for which  
28 DrugLogic offers a broader construction; Oracle offers the same proposed construction for both claim  
terms.

1           **B. The ‘221 Claim Terms**2           **1. “Clinical Terms” (Claim 1)**

3           Oracle’s Proposed Construction	4           DrugLogic’s Proposed Construction
5           No construction required 6           or 7           “Terms pertaining to the study or observation 8           of medical patients, such as terms in a medical dictionary”	“Terms pertaining to the study or observation of medical patients”

9           **a. Parties’ Positions**

10           Oracle contends that “clinical terms” is a commonly understood phrase with no special  
11 meaning in the context of the ‘221 patent and therefore, that it requires no construction. Oracle’s  
12 Opening Brief Regarding Construction of Disputed Terms in the ‘221 patent (“Oracle’s Opening  
13 Brief (‘221 patent)”) at 6. In the alternative, if the Court concludes that construction is necessary,  
14 Oracle argues that it should adopt Oracle’s proposed construction, which differs from DrugLogic’s  
15 construction only to the extent it includes the exemplary phrase “such as terms in a medical  
16 dictionary.” *Id.* at 7. This phrase should be included, Oracle asserts, because “[a]t the heart of this  
17 dispute is whether terms in a medical dictionary are ‘clinical terms’” within the meaning of the ‘221  
18 patent. *Id.*

19           Oracle points to the specification in support of its contention that “clinical terms” includes  
20 terms from a medical dictionary. *Id.* In particular, the specification describes a preferred  
21 embodiment in which “[t]he clinical terms are initially transmitted to the thesaurus database 18 from  
22 an external media source, such as a CD-ROM.” *Id.* (quoting ‘221 patent, col. 3, ll. 40- 43). The  
23 “external media source,” in turn, is described as follows:  
24

25           Typically, external media sources are purchased in the form of a dictionary on a CD-ROM  
26 from an external vendor. Common vendor-supplied dictionaries include WHO-Drug (World  
27 Health Organization Drug Dictionary) by the World Health Organization, COSTART  
28 (Coding Symbols for a Thesaurus of Adverse Reaction Terms) by the Drug Information  
Association, and CPT (Current Procedural Terminology) by the American Medical  
Association. Other vendors and dictionaries are common and known in the industry.

1 ‘221 patent, col. 4, ll. 2-11. In addition, Oracle points to the description of Figure 7, referring to  
2 terms from vendor-supplied dictionaries as “clinical terms.” Oracle Opening Brief (‘221 patent) at 7  
3 (quoting ‘221 patent, col. 7, ll. 9-11) (“Referring to Fig. 7, there are several types of terms which  
4 may be stored in the thesaurus database as clinical terms”). Further, Figure 7 shows that the medical  
5 dictionary supplied terms are included in the broader category of “clinical terms.” *Id.* at 8 (citing  
6 ‘221 patent, Fig. 7). DrugLogic’s proposed construction is improper, Oracle asserts, because it  
7 would exclude terms derived from medical dictionaries, thereby excluding the preferred embodiment  
8 shown in Figure 7. *Id.* (citing *Vitronics Corp. v. Conceptronics, Inc.*, 90 F.3d 1576, 1584 (Fed. Cir.  
9 1996)).

10 In its responsive claim construction brief, DrugLogic states that it would agree that “the term  
11 ‘clinical term’ alone does not require construction” if it were not for the exemplary language Oracle  
12 has requested as part of its construction (“such as terms in a medical dictionary”). DrugLogic, Inc.’s  
13 Corrected Responsive Claim Construction Brief on United States Patent No. 6,684,221  
14 (“DrugLogic’s Responsive Brief (‘221 patent)” at 12 n. 10. DrugLogic concedes that the ordinary  
15 meaning of “clinical terms,” outside the context of the ‘221 patent, would include terms from a  
16 medical dictionary. *Id.* at 11 (“terms in a prior art medical dictionary may be ‘clinical’ in the sense  
17 that they may relate to the treatment of a patient”). It also does not dispute that the specification  
18 describes a preferred embodiment in which “clinical terms” are drawn from a medical dictionary.  
19 *Id.* at 11-16. It argues, however, that the claims, read as a whole, support a more limited  
20 construction of the phrase “clinical terms,” especially in light of the prosecution history. *Id.*

21 DrugLogic points out that claim 1 recites, in part, “[a] method for storing a thesaurus of  
22 clinical terms comprising: defining a plurality of *clinical terms for use in conjunction with a clinical*  
23 *study . . .*” *Id.* at 9 (quoting ‘221 patent, col. 9, ll. 16-17) (emphasis in DrugLogic’s brief). The  
24 language in italics, DrugLogic contends, makes clear that “clinical terms” recited in the claims “are  
25 *not just any clinical terms*, for example clinical terms that might be found in a medical dictionary.”  
26 *Id.* at 10. Rather, they must be related to a particular clinical study. *Id.* This is because “the entire  
27 purpose of the invention is to build a thesaurus of clinical terms that are not already contained in an  
28

1 existing medical/clinical thesaurus,” DrugLogic asserts. *Id.* at 11. In other words, DrugLogic  
2 contends, “[t]he invention allows a user to add new clinical terms from a clinical study to an existing  
3 medical thesaurus, to structure the new terms in accordance with a hierarchy, and to define  
4 relationships between the added terms and previously loaded terms in the database.” *Id.* at 5. To the  
5 extent clinical terms contained in a medical dictionary are not necessarily related in any way to a  
6 clinical study, DrugLogic asserts, such terms do not fall within the scope of the claims. *Id.*  
7 DrugLogic concedes that the specification describes a preferred embodiment in which terms from a  
8 medical dictionary are described as “clinical terms.” *Id.* at 10-11. It argues, however, that the  
9 language of the claim must “prevail over inconsistent language in the specification.” *Id.* (citing  
10 *Elekta Instrument S.A. v. O.U.R. Scientific Int'l, Inc.*, 214 F.3d 1302, 1308 (Fed. Cir. 2000)).

11 Similarly, DrugLogic argues that the doctrine of prosecution history disclaimer limits the  
12 phrase “clinical terms” to exclude terms from medical dictionaries. *Id.* at 12-16. In particular,  
13 DrugLogic argues that the applicant amended all of the claims to overcome a final rejection “to  
14 specify, with more particularity, that the invention relates to a thesaurus of clinical terms *for use in*  
15 *conjunction with a clinical study.*” *Id.* at 13 (emphasis in DrugLogic’s brief). DrugLogic points to  
16 the following arguments made by the applicant in support of allowance of the amended claims:

17 ... Gusack was cited by the Office to show the hierarchy of relations, but Gusack does not  
18 relate to the claimed hierarchy of relations *used in conjunction with a clinical study*. . . .  
19 There is nothing in Gusack or in any other cited reference that suggests that clinical terms  
should be stored in a thesaurus of terms according to a hierarchy of relations for use in  
conjunction with a clinical study.

20 In fact, none of the cited references relate to clinical studies. Further, the references do not  
21 address the issues associated with clinical studies, such as the inconsistencies in terminology  
in the medical field. With the claimed invention, however, clinical terms for a clinical study  
22 are stored according to a hierarchy of relations . . .

23 *Id.*, Ex. 9, p. 8 (underlining in original; bold-italics added by DrugLogic). Based on this language,  
24 DrugLogic contends that the “applicant unequivocally disclaimed a thesaurus of clinical terms  
25 wherein the terms are compiled from sources other than clinical studies, such as existing medical  
26 dictionaries.” *Id.* (citing *Seachange Int'l, Inc. v. C-COR Inc.*, 413 F.3d 1361, 1375 (Fed. Cir. 2005);  
27 *Rheox, Inc. v. Entact, Inc.*, 276 F.3d 1319, 1325 (Fed. Cir. 2002); *Andersen Corp. v. Fiber*

1 *Composites, LLC*, 474 F.3d 1361, 1368-69 (Fed. Cir. 2007)). Accordingly, DrugLogic argues, the  
2 phrase “clinical terms” cannot be construed to encompass clinical terms from vendor supplied  
3 medical dictionaries, even though the specification of the ‘221 patent describes an embodiment in  
4 which “clinical terms” are obtained from such external sources. *Id.* at 15.

5 DrugLogic further contends that Oracle’s proposed construction would render the patent  
6 invalid because claim 1 would claim an invention that was essentially the same as the existing prior  
7 art medical dictionaries. *Id.* at 16. Because the Court should construe the term to preserve its  
8 validity, DrugLogic asserts, Oracle’s proposed construction should be rejected. *Id.* (citing *Rhine v.*  
9 *Casio, Inc.*, 183 F.3d 1342, 1345 (Fed. Cir. 1999)).

10 In its reply brief, Oracle argues that DrugLogic’s reliance on the doctrine of prosecution  
11 disclaimer is misplaced and that DrugLogic has mischaracterized the prosecution history. Oracle’s  
12 Reply Brief Regarding the Construction of Disputed Terms in the ‘221 patent (“Oracle Reply Brief  
13 (‘221 patent)”) at 3. According to Oracle, DrugLogic has incorrectly suggested that the PTO  
14 rejected the claims, as originally drafted, because existing medical dictionaries rendered them  
15 obvious, requiring the applicant to narrow the claims to exclude terms from medical dictionaries. *Id.*  
16 In fact, Oracle contends, the prior art cited by the Examiner as grounds for rejection did not include  
17 *any* medical dictionaries. *Id.* at 3-4. Consequently, the applicant’s amendments did not address  
18 whether “clinical terms” could be drawn from preexisting medical dictionaries. *Id.* at 5. Under  
19 these circumstances, there was no clear disclaimer of claim scope, Oracle contends. *Id.* at 8-9.

20 Furthermore, Oracle argues, the language of the claims does not support DrugLogic’s  
21 position. *Id.* at 7. According to Oracle, DrugLogic wrongly equates the phrase “for use in” with the  
22 phrase “to derive from.” *Id.* (quoting DrugLogic’s assertion that “Oracle’s proposed construction of  
23 ‘clinical terms’ including the exemplary phrase, ‘such as terms in a medical dictionary,’ is  
24 inappropriate as the applicant unequivocally disclaimed an invention including clinical terms  
25 **derived from** sources other than clinical studies, such as existing medical dictionaries, during  
26 prosecution” and that “[t]he applicant unequivocally disclaimed an invention including clinical  
27 terms *derived from* sources other than clinical studies, such as existing medical dictionaries”). *Id.* at  
28

1 7. Oracle argues, “the basic invention of the ‘221 patent is a method of creating a thesaurus of  
 2 clinical terms by gathering those terms from various sources, including standardized medical  
 3 dictionaries, company terms, and elsewhere, and building them into one hierarchical, relational  
 4 thesaurus of terms.” *Id.* According to Oracle, “[t]hat the stated *purpose* of this thesaurus of clinical  
 5 terms is ‘for use in conjunction with a clinical study’ has nothing logically to do with the potential  
 6 *sources* of the clinical terms.” *Id.*

7 Finally, Oracle rejects DrugLogic’s contention that Oracle’s proposed construction would  
 8 render the claims invalid over standardized medical dictionaries. *Id.* at 9. Oracle argues that  
 9 DrugLogic has offered no charts or details about any prior art showing that the claims would be  
 10 invalid and that in fact, standard medical dictionaries do not teach every aspect of the ‘221  
 11 invention. *Id.* at 9-10. Oracle also argues that the argument is premature to the extent it goes to  
 12 validity and that in any event, claims should be construed to preserve validity only “if possible.” *Id.*

13 **b. Analysis**

14 In “rare case[s]” in which the language of an amended claim is unambiguous and there was a  
 15 clear disclaimer of claim scope during the prosecution of a patent, a construction that excludes a  
 16 preferred embodiment may be “compelled.” *Elekta Instrument S.A. v. O.U.R. Scientific Intern.*,  
 17 214 F.3d 1302, 1308 (Fed. Cir. 2000). This is not such a case. Contrary to DrugLogic’s assertions,  
 18 the language of the claims does not clearly support the exclusion of clinical terms from medical  
 19 dictionaries and thesauruses; nor does the prosecution history show a clear disclaimer of  
 20 embodiments in which the claim term “clinical terms” encompasses terms derived from existing  
 21 medical dictionaries or thesauruses. Therefore, the Court adopts Oracle’s proposed construction.<sup>11</sup>

22 As to the claim language, DrugLogic’s position fails as a matter of grammar: the requirement  
 23 that clinical terms must be “for use in conjunction with a clinical study” says nothing that suggests  
 24

---

25 <sup>11</sup>The Court concludes that construction of this term is appropriate because failure to construe  
 26 “clinical terms” would leave unresolved a key dispute between the parties. See *O2 Micro Intern. Ltd.*  
*v. Beyond Innovation Technology Co., Ltd.*, 521 F.3d 1351, 1361 (Fed. Cir. 2008)(holding that even if  
 27 a claim term has a plain and ordinary meaning, the court should construe the term if construction is  
 28 required to resolve a dispute about the scope of the asserted claims, which is a question of law to be  
 decided by the Court ).

1 those terms must be *derived from* a clinical study, much less a particular clinical study, as  
2 DrugLogic contends. Nor does the specification support DrugLogic's contention that the "entire  
3 purpose of the invention is to build a thesaurus of clinical terms that are not already contained in an  
4 existing medical/clinical thesaurus." To the contrary, the specification describes a preferred  
5 embodiment in which "clinical terms" expressly include terms from an existing dictionary or  
6 thesaurus, as DrugLogic concedes.

7 Further, the prosecution history does not support DrugLogic's position that the applicant  
8 limited the scope of the invention to exclude clinical terms from a medical dictionary. Rather, the  
9 applicant argued that the invention claimed in claim 1 (and other claims with similar language) was  
10 patentable over the prior art referenced by the Examiner because: 1) Coulter, while reciting an  
11 indexing system that can provide a thesaurus table with unique terms from text documents and stores  
12 links between the terms and their respective text documents, "does not suggest that the terms should  
13 be stored according to a hierarchy of relations;" 2) Gusack "is directed to defining data clusters such  
14 that links are not made directly between any two records but, instead, are made between groups of  
15 records stored in a plurality of tables in a date set" and therefore, "nothing in Gusack . . . suggests  
16 that clinical terms should be stored in a thesaurus of terms according to a hierarchy of relations for  
17 use in conjunction with a clinical study;" and 3) "none of the cited references relate to clinical  
18 studies" and "the references do not address the issues associated with clinical studies, such as the  
19 inconsistencies in terminology in the medical field" – difficulties that are addressed in the '221  
20 invention by use of a "hierarchy of relations [that] allows the clinical terms to be organized  
21 according to degrees of more general and more specific terms." Von Der Ahe Reply Decl., Ex. I  
22 (June 9, 2003 Applicants Response) at 8 (emphasis in original).<sup>12</sup>

23 In short, none of the arguments in support of allowance even addressed the question of  
24 whether "clinical terms" included terms in existing medical dictionaries. The only argument that  
25 comes close to addressing this issue is the argument that the prior art was not related to clinical  
26

---

27 <sup>12</sup>In the Reasons for Allowance, the Examine stated that these arguments were persuasive. Von  
28 Der Ahe Decl., Ex. J at 2-3.

1 studies at all, and therefore did not address the problems that the '221 invention was intended to  
 2 address. As discussed above, however, requiring that the clinical terms be "for use in conjunction  
 3 with a clinical study" is not the same as requiring that they be derived exclusively from such a study,  
 4 to the exclusion of terms contained in existing medical dictionaries. Certainly, these arguments do  
 5 not amount to an "unequivocal" disavowal of claim scope with respect to the term "clinical terms."

6 The Court also does not find persuasive DrugLogic's conclusory statement that Oracle's  
 7 proposed construction would render the '221 patent invalid. Assuming it is appropriate to consider  
 8 at the claim construction phase of the case whether a particular construction would render a patent  
 9 invalid, DrugLogic has not offered sufficient evidence to show that any particular prior art reference  
 10 would anticipate or render the '221 patent obvious under Oracle's proposed construction of "clinical  
 11 terms."

12 The Court therefore construes "clinical terms" as follows: "terms pertaining to the study or  
 13 observation of medical patients, such as terms in a medical dictionary."

14 **2. "defining a plurality of clinical terms for use in conjunction with a  
 15 clinical study" (Claim 1)**

16 Oracle's Proposed Construction	17 DrugLogic's Proposed Construction
17 No construction required 18 or 19 "choosing a plurality of terms pertaining to the 20 study or observation of medical patients for use 21 in conjunction with a clinical study"	22 "developing a list of terms pertaining to the 23 study or observation of medical patients used in 24 connection with a particular clinical study"

22 **a. Parties' Positions**

23 Oracle contends that this claim term requires no construction because it is "nontechnical . . .  
 24 and understandable to anyone." Oracle's Opening Brief ('221 patent) at 9. If the Court decides that  
 25 construction is necessary, Oracle asserts that its proposed construction is most faithful to the plain  
 26 and ordinary meaning of the term and the language of the patent. *Id.* Oracle highlights the use of  
 27 the word "choosing" in its proposed construction, arguing that this is consistent with the teaching of  
 28 the patent that clinical terms can be chosen in a variety of ways, including choosing them from a

1 standard medical dictionary, using terms customized for a particular study (“domain terms”) or using  
2 terms that are in use with a user’s company. *Id.* (citing ‘221 patent, col. 6, ll. 9-24). In particular,  
3 the specification describes a preferred embodiment depicted in Fig.7 as follows:

4 Referring to Fig. 7, there are several types of items which may be stored in the thesaurus  
5 database 18 as clinical terms 400. External terms 402 are loaded from vendor supplied  
6 dictionaries, typically from a CD-ROM, and loaded at one time. Company terms 402 are  
7 those specific to a particular company or enterprise, and are added to the thesaurus database  
8 18 as needed to support the classification processing. Domain terms 404 are attributed to a  
9 particular study, and contain unpublished terms specific to the study.

10 ‘221 patent, col 7, ll. 9-18.

11 Oracle further asserts that the words of the claims support its proposed construction. Oracle  
12 Opening Brief (‘221 patent) at 9-10. Specifically, Oracle points to dependent claim 43, which  
13 recites “[t]he system of claim 42 wherein the external media source is a medical dictionary.” *Id.*  
14 According to Oracle, the “external media source” in claims 14, 16 and 17 is where the clinical terms  
15 are obtained and defined. *Id.* at 10.

16 Oracle asserts that DrugLogic’s proposed construction is wrong for several reasons. *Id.*  
17 First, the word “developing” in its proposed construction, in combination with the words “used in  
18 connection with a particular clinical study,” limits the claim term – as well as the phrase that  
19 follows, “storing the plurality clinical terms in a memory according to a hierarchy of relations” – to  
20 customized clinical terms created by the user, thereby excluding the preferred embodiment. *Id.*  
(citing *Vitronics*, 90 F.3d at 1583).

21 Second, Oracle contends that DrugLogic’s proposed construction is inconsistent with the  
22 intrinsic evidence to the extent it limits clinical terms to those associated with a “particular study”  
23 because the specification only refers to a “particular” study when it is describing domain terms. *Id.*  
24 (citing ‘221 patent, col. 7, ll. 16-17, col. 5, ll. 57-58). The words “clinical terms” in this claim term  
25 have a broader meaning, Oracle asserts, encompassing terms from medical dictionaries, company  
26 terms and domain terms. *Id.*

27 Third, Oracle argues that DrugLogic’s proposed construction is incorrect because when the  
28 inventor intended to confine the claims to a particular study, he knew how to do so. *Id.* Oracle

1 points out that claim 38, which depends from claim 22, is “addressed to ‘a system for accessing a  
2 thesaurus of clinical terms used in conjunction with a clinical study’ . . . ‘wherein the match terms  
3 include common global terms and *domain* terms corresponding to *a particular study*.’” *Id.* (quoting  
4 claim 22 (partial) and claim 38 (partial) (emphasis added)). Oracle also points to claim 15, which  
5 “refers to clinical terms being ‘enterprise terms corresponding to a company and *domain* terms  
6 corresponding to a *predetermined study*.’” *Id.* at 10-11 (quoting claim 15) (emphasis in Oracle’s  
7 brief). Oracle argues that “[b]ecause the patentee differentiated clinical studies from ‘particular’  
8 clinical studies elsewhere in the patent, importing this limitation into Claim 1 would be improper.”  
9 *Id.* (citing *Phillips*, 415 F.3d at 1315).

10 Fourth, Oracle argues that DrugLogic’s proposed construction is incorrect because it would  
11 eliminate the distinction between external, company and domain terms, and would render  
12 synonymous “clinical terms” and “domain terms.” *Id.* at 11. In doing so, it would conflict with the  
13 specification by reading out a preferred embodiment and would render claims redundant, a result  
14 that should be avoided. *Id.* at 11.

15 DrugLogic argues that while its proposed construction admittedly excludes a preferred  
16 embodiment, it is proper in light of the prosecution history under the doctrine of prosecution  
17 disclaimer, for the same reasons discussed above in connection with the term “clinical terms.”  
18 DrugLogic Responsive Brief (‘221 patent) at 19-20. Because of the applicant’s disavowal of claim  
19 scope, DrugLogic argues, the words “clinical terms” in this claim term include only “domain terms”  
20 (which are undisputedly specific to a particular study) and company terms that arise out of or relate  
21 to a particular clinical study. *Id.* at 18 & n. 13. DrugLogic argues that Oracle’s reliance on the  
22 doctrine of claim differentiation fails because the presumption of claim differentiation is rebuttable  
23 and the presumption is rebutted here on the basis of the narrowing amendments made during patent  
24 prosecution. *Id.* at 19-20. DrugLogic further asserts that Oracle’s proposed construction would  
25 render the claims invalid. *Id.* at 20.

26 In its reply brief, Oracle notes that DrugLogic does not address in its responsive brief  
27 Oracle’s assertion that this claim term would be understandable to a lay person and therefore  
28

1 requires no construction. Oracle Reply Brief ('221 patent) at 10. Oracle further counters that  
2 DrugLogic's reliance on the specification's use of the term "particular" in connection with its  
3 description of domain terms does not warrant importing this limitation into the construction of this  
4 claim term. Oracle Reply Brief ('221 patent) at 11. Finally, Oracle argues that DrugLogic's  
5 reliance on the doctrine of prosecution disclaimer fails for the reasons discussed above. *Id.* at 11.

## b. Analysis

7 DrugLogic's proposed construction of this claim term is based on its contention that the  
8 applicant narrowed the scope of the '221 claims to exclude clinical terms obtained from medical  
9 dictionaries and thesauruses. As discussed above, the Court finds that DrugLogic's reliance on the  
10 doctrine of prosecution disclaimer is misplaced on this question. Because the applicant did not  
11 clearly disavow embodiments in which clinical terms are drawn from medical dictionaries and  
12 thesauruses, the construction proposed by DrugLogic is inconsistent with the specification. In  
13 particular, the specification explains that the invention can be implemented using three types of  
14 clinical terms – those drawn from medical dictionaries and thesauruses, company terms and domain  
15 terms. *See* '221 patent, col. 7, ll. 9-18. It further explains that clinical terms from a *particular study*  
16 are "domain terms." *Id.* DrugLogic's proposed construction also fails under the doctrine of claim  
17 differentiation to the extent that certain dependent claims limit the scope of the claims to domain  
18 terms limited to particular studies. *See, e.g.*, Claims 15, 38. Therefore, the Court adopts Oracle's  
19 proposed construction of the term "defining a plurality of clinical terms for use in conjunction with a  
20 clinical study," that is, "choosing a plurality of terms pertaining to the study or observation of  
21 medical patients for use in conjunction with a clinical study."

### 3. Verbatim Clinical Data (Claim 12)

Oracle's Proposed Construction	DrugLogic's Proposed Construction
<p>No construction required or “raw information related to the study or observation of medical patients”</p>	<p>“exact word-for-word raw clinical data from a clinical study”</p>

### a. Parties' Positions

According to Oracle, the parties disagree as to this claim term on two questions: 1) whether “verbatim” means “raw” (Oracle), or “exact word-for-word raw” (DrugLogic); and 2) whether “clinical data” means “information related to the study or observation of medical patients” (Oracle) or “clinical data from a clinical study” (DrugLogic). Oracle’s Opening Brief (‘221 patent) at 12.

6 As to the first question, Oracle contends that its proposed construction is correct because  
7 “throughout the specification, the patent refers to verbatim data as ‘raw’ data.” *Id.* (citing ‘221  
8 Abstract (“A study term extracted from raw clinical data is presented to determine a corresponding  
9 match in the thesaurus of clinical terms”); col. 2, ll. 8-11 (“The system and method classify the terms  
10 derived from raw clinical data to effect a consistent clinical term classification throughout the  
11 clinical study”)).<sup>13</sup> Because the parties agree, according to Oracle, that “clinical data” means “at  
12 minimum, ‘pertaining to the study or observation of medical patients,’ . . . Oracle’s proposed  
13 construction of ‘verbatim clinical data’ as ‘raw information related to the study or observation of  
14 medical patients’ merely combines these agreed-upon elements and explains that ‘data’ is  
15 ‘information.’” *Id.* at 12-13. Oracle asserts that DrugLogic’s proposed construction of “verbatim” as  
16 “exact word-for-word raw” is confusing because it includes three possible meanings for “verbatim”  
17 – exact, word-for-word, and raw. *Id.* at 13. Further, Oracle contends, this definition “may imply  
18 that the entirety of the raw clinical data needs to be scanned.” *Id.*

19 As to the second question, Oracle argues that DrugLogic’s definition of “clinical data” as  
20 “clinical data from a clinical study” is improper because it includes the claim term in the definition  
21 of the claim term, which is not appropriate in claim construction. *Id.* (citing *Volterra Semiconductor*  
22 *Corp. v. Primarion, Inc.*, 2009 WL 6357679, at \* 11 (N.D. Cal. Nov. 17, 2009)). Oracle asserts that  
23 DrugLogic is attempting to “tack a limitation onto the claim that does not exist in the claim language

<sup>26</sup> <sup>13</sup>Oracle notes in a footnote, citing Cobert's Manual of Drug Safety and Pharmacovigilance, that verbatim terms are generally "terms used by reporters, patients and investigators" rather than terms from a medical dictionary. *Id.* at 12 n. 4; Baker Decl., Ex. B at 80. It also notes that the parties have agreed that the term "verbatim study terms" means "exact words included in raw clinical data."

<sup>27</sup>

1 itself . . . by suggesting that the only verbatim data relevant here are those derived from clinical  
2 studies.” *Id.* Oracle contends that such a construction would exclude “data collected from, *e.g.*,  
3 doctors observing patients in their day-to-day clinical practices, pharmacists reporting customer  
4 feedback, and patient-initiated reports of adverse effects.” *Id.* According to Oracle, “[n]othing in  
5 the language of the patent suggests an intent to exclude such information.” *Id.*

6 DrugLogic defends its proposed construction of “verbatim data” as “exact word-for-word  
7 raw clinical data” rather than merely “raw clinical data,” arguing that Oracle’s proposed construction  
8 “essentially removes the word ‘verbatim’ from the construction of ‘verbatim clinical data’ in claim  
9 12.” DrugLogic Responsive Brief (‘221 patent) at 20. Because a claim construction should give  
10 meaning to all the terms of the claim, DrugLogic contends, Oracle’s proposed construction should  
11 be rejected. *Id.* at 20-21. Further, DrugLogic asserts, the plain meaning of the word “verbatim” is  
12 “exact word-for-word.” *Id.* at 21 & Ex. 12 (definition from dictionary.com, defining “verbatim” as  
13 “In exactly the same words; word-for-word”), Ex. 13. (definition from Webster’s on-line dictionary  
14 defining “verbatim” as “in the exact words, word-for-word”). DrugLogic also offers the following  
15 excerpt from the specification in support of its proposed construction:

16 The verbatim study terms 26 are provided from clinical data 38 by any suitable method,  
17 including the scanner 34 from hardcopy data reports, the PC 36 from a data entry or other  
18 suitable application, or a public access network such as the Internet 38 via an HTML browser  
19 or other format. **The raw, unprocessed clinical data** 38 is then interrogated for verbatim  
study terms 26 to provide to the input device 14 for classification. In a particular  
embodiment, the **raw, unprocessed clinical data** 38 is received by a clinical study data  
management application.

20 *Id.* (quoting ‘221 patent, col. 3, ll. 51-62) (emphasis added by DrugLogic). According to  
21 DrugLogic, this passage supports its proposed construction because the word “unprocessed” refers  
22 to the fact that the “verbatim data” is in its “unchanged, original form.” *Id.* Similarly, DrugLogic  
23 asserts, the prosecution history supports DrugLogic’s proposed construction because the applicants  
24 referred to “deriving clinical terms . . . from free text as originally captured.” *Id.* & Ex. 9 (excerpt of  
25 prosecution history) at 7.

26 DrugLogic argues that its construction of “clinical data” as “clinical data from a clinical  
27 study” is consistent with the specification, the language of claim 12 and the prosecution history. *Id.*  
28

1 at 21-22. DrugLogic points to the following statements in the specification in support of its  
2 position: “the same clinical term may appear in a variety of formats throughout the clinical data  
3 produced by the study” (‘221 patent, col. 1, ll. 42-43); “In a typical study, verbatim study terms 26  
4 are extracted from raw clinical data by a variety of methods . . .” (‘221 patent, col. 3, ll. 34-35); and  
5 “In a particular embodiment, the raw, unprocessed clinical data 38 is received by a clinical study  
6 data management application . . .” (‘221 patent, col. 3, ll. 58-60). DrugLogic further contends that a  
7 plain reading of claim 12 as a whole “leaves no doubt that the verbatim clinical data must come from  
8 a clinical study.” *Id.* at 22. Finally, DrugLogic cites the following passage in the prosecution  
9 history in support of its position:

10 By way of background, a clinical study is typically a research process by which clinical data  
11 is gathered, such that it assists a user in answering scientific questions and determining  
12 whether certain methods of prevention, diagnosis, and treatment are safe or effective. Ideally  
13 in this process, the clinical data is gathered, captured, classified and organized. One of the  
14 most time-consuming tasks within the clinical trial process is classifying and organizing the  
15 clinical data.

16 *Id.* (quoting Ex. 9 at 7-8).

17 Oracle argues in its reply brief that DrugLogic has implicitly conceded that the ‘221 patent  
18 uses the terms “raw” and “verbatim” interchangeably and yet offers no explanation for the inclusion  
19 of “further verbiage” in its proposed construction. Oracle Reply Brief (‘221 patent) at 12. Further,  
20 Oracle argues, DrugLogic has made “no attempt to address Oracle’s reasoned argument” that  
21 DrugLogic’s proposed construction confusingly suggests that all of the raw data must be scanned.  
22 *Id.* Oracle also asserts that DrugLogic has failed to address its argument that it is improper to limit  
23 “clinical data” to that which is obtained from clinical studies. *Id.*

24 **b. Analysis**

25 The primary disputes the Court must resolve with respect to the claim term “verbatim clinical  
26 data” are: 1) whether the term requires construction; 2) how “verbatim” should be construed; and 3)  
27 whether “clinical data” must be obtained from clinical studies or rather may be obtained from other  
28 types of reports as well . While it is not clear that there is any significant dispute regarding the  
meaning of “verbatim,” the parties’ positions as to the meaning of the words “clinical data” reflect a

1 more fundamental disagreement that must be decided by the Court as a matter of law. Therefore, the  
2 Court finds that it is necessary to construe this claim term.

3 As to the word “verbatim,” Oracle criticizes DrugLogic’s proposed construction on the basis  
4 that it is based, in part, on extrinsic evidence. It does not, however, dispute that the word, as used in  
5 the ‘221 patent, carries its ordinary and customary meaning, that is, “in exactly the same words” or  
6 “word-for-word.” The Court agrees with DrugLogic that Oracle’s proposed construction does not  
7 adequately capture this meaning: while it makes clear that the data is drawn from raw data, it does  
8 not reflect the fact that this data is not changed or processed in any way, but rather, is scanned word-  
9 for-word. In the specification, the applicant conveyed this meaning by describing the data as “raw,  
10 *unprocessed* clinical data.” See, e.g., ‘221 patent, col. 3, ll. 58-60. During prosecution, the concept  
11 was conveyed by describing the verbatim clinical data as “free text *as originally captured*.”  
12 DrugLogic Responsive Brief (‘221 patent), Ex. 9 (excerpt of prosecution history) at 7. Therefore,  
13 the Court includes in its construction language that conveys that the clinical data is taken word-for-  
14 word from the raw data. The possibility of confusion relating to whether an entire piece of data must  
15 be scanned – cited by Oracle in support of its opposition to DrugLogic’s proposed construction –  
16 does not appear to the Court to be significant, as nothing in DrugLogic’s proposed construction  
17 states such a requirement. Nonetheless, given that DrugLogic does not appear to dispute Oracle’s  
18 contention that an *excerpt* of raw data falls within the scope of the claim, this concern can be  
19 addressed by inserting additional language making clear that an excerpt is sufficient.

20 As to the words, “clinical data,” the Court concludes that these words refer to information  
21 from clinical studies. The plain meaning of these words, as well as at least two passages in the  
22 specification, support this conclusion. *See* ‘221 patent, col. 1, ll. 23-31 (“[C]linal studies are often  
23 undertaken during preparation of a new consumer product. . . . a large quantity of clinical data is  
24 generated by such studies”), col. 3, 34-35 (“In a typical study, verbatim study terms 26 are extracted  
25 from raw clinical data . . . “). Further, the language of claim 12 supports the conclusion that  
26 “clinical data” comes from clinical studies, reciting “scanning verbatim clinical data” and “parsing

27

28

1 verbatim *study terms* from the clinical data.” Because the parties have already stipulated to the  
2 meaning of “clinical studies,”<sup>14</sup> the Court need not further construe the words “clinical data.”

3       Based on the foregoing, the Court construes “verbatim clinical data” as “raw, word-for word  
4 information, whether in its entirety or in excerpted form, from a clinical study.”

## 5 || V. CONCLUSION

6 For the reasons discussed above, the Court adopts the following constructions:

Claim Term	Court's Construction
“allowing analytical drill down”	“allowing a user to redo the analysis in real time at different levels of the hierarchy”
“hyperlinks . . . corresponding to places in an up and down hierarchy”	“such links . . . corresponding to different levels of a structured medical dictionary, such as MedDRA”
“associating respective hyperlinks with a plurality of portions of such data and analysis”	“creating a plurality of links within web pages for some of the previously stored information and some of the results of the statistical analysis such that clicking on the information or results causes a user to jump to another place in the same web page or to an entirely different web page”
“permitting the at least one remote user to analyze safety issues”	“permitting the at least one remote user to run a statistical analysis that finds ‘signals’ such as anomalies in a random population, changes against a known background, or coherent targets in a noise background”
“permitting at least one remote user to access such data through the World Wide Web”	“permitting a user at one computer to access information reflecting occurrences of adverse events on a different computer or server, through one or more Internet servers”
“a comparator to measure the reactions to the at least one [drug/substance] of interest against a user-defined backdrop”	“an application that compares the reactions to a particular drug of two user-defined data sets”
“comparator”	


26       <sup>14</sup>“Clinical studies” is construed by the parties to mean “a research process by which clinical  
27 data is gathered in order to answer scientific questions and determine whether certain methods of  
28 prevention, diagnosis, and treatment are safe or effective.” Joint Claim Construction and Prehearing  
Statement [Docket No. 102] at 4.

1	“a correlator to look for correlated signal 2 characteristics among drug, reaction, and 3 demographic information” 4 “correlator”	“an analysis tool that concurrently searches 5 drug, reaction and demographic information to 6 measure the degree of association among pairs 7 of certain drug, reaction, and demographic 8 values”
4	“clinical terms”	“terms pertaining to the study or observation of 5 medical patients, such as terms in a medical 6 dictionary”
6	“defining a plurality of clinical terms for use in 7 conjunction with a clinical study”	“choosing a plurality of terms pertaining to the 8 study or observation of medical patients for use 9 in conjunction with a clinical study”
8	“verbatim clinical data”	“raw, word-for word information, whether in its 9 entirety or in excerpted form, from a clinical study”

10  
11 The Court will hold a further case management conference on September 21, 2012 at 1:30  
12 p.m. On or before September 14, 2012, the parties shall file a joint case management conference  
13 statement containing a proposed schedule for the remainder of the case.

14 IT IS SO ORDERED.

15  
16 Dated: August 21, 2012

17  
18  
19  
20   
JOSEPH C. SPERO  
21 United States Magistrate Judge  
22  
23  
24  
25  
26  
27  
28